U.S. patent application number 14/333349 was filed with the patent office on 2014-11-06 for drug delivery methods, structures, and compositions for nasolacrimal system.
The applicant listed for this patent is Mati Therapeutics. Invention is credited to Stephen Boyd, Eugene de Juan, JR., Mark Deem, Hanson S. Gifford, Cary Reich.
Application Number | 20140328894 14/333349 |
Document ID | / |
Family ID | 38564290 |
Filed Date | 2014-11-06 |
United States Patent
Application |
20140328894 |
Kind Code |
A1 |
de Juan, JR.; Eugene ; et
al. |
November 6, 2014 |
DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR
NASOLACRIMAL SYSTEM
Abstract
An implant for insertion into a punctum of a patient comprises a
body. The body has a distal end, a proximal end, and an axis
therebetween. The distal end of the body is insertable distally
through the punctum into the canalicular lumen. The body comprises
a therapeutic agent included within an agent matrix drug core.
Exposure of the agent matrix to the tear fluid effects an effective
therapeutic agent release into the tear fluid over a sustained
period. The body has a sheath disposed over the agent matrix to
inhibit release of the agent away from the proximal end. The body
also has an outer surface configured to engage luminal wall tissues
so as to inhibit expulsion when disposed therein. In specific
embodiments, the agent matrix comprises a non-bioabsorbable
polymer, for example silicone in a non-homogenous mixture with the
agent.
Inventors: |
de Juan, JR.; Eugene; (San
Francisco, CA) ; Reich; Cary; (Los Gatos, CA)
; Boyd; Stephen; (Murrieta, CA) ; Gifford; Hanson
S.; (Woodside, CA) ; Deem; Mark; (Mountain
View, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Mati Therapeutics |
Austin |
TX |
US |
|
|
Family ID: |
38564290 |
Appl. No.: |
14/333349 |
Filed: |
July 16, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11695537 |
Apr 2, 2007 |
8795711 |
|
|
14333349 |
|
|
|
|
60787775 |
Mar 31, 2006 |
|
|
|
60871864 |
Dec 26, 2006 |
|
|
|
Current U.S.
Class: |
424/427 ;
514/20.8; 514/570; 514/622; 604/175; 604/285 |
Current CPC
Class: |
A61P 43/00 20180101;
A61F 9/0017 20130101; A61P 29/00 20180101; A61K 9/00 20130101; A61K
31/215 20130101; A61F 9/00781 20130101; A61F 2220/0008 20130101;
A61F 2250/0087 20130101; A61K 31/216 20130101; A61K 9/0017
20130101; A61K 31/573 20130101; A61K 31/557 20130101; A61K 9/06
20130101; A61L 31/16 20130101; A61K 31/55 20130101; A61F 9/00772
20130101; A61K 9/0051 20130101; A61P 27/02 20180101; A61F 2250/0067
20130101; A61K 31/5575 20130101; A61P 9/00 20180101; A61K 47/34
20130101; A61F 9/0026 20130101; A61P 31/04 20180101; A61P 27/06
20180101 |
Class at
Publication: |
424/427 ;
514/622; 514/570; 514/20.8; 604/175; 604/285 |
International
Class: |
A61F 9/00 20060101
A61F009/00 |
Claims
1. An implant for insertion into a punctum of a patient, the
punctum providing a flow path for a tear fluid from an eye to a
canalicular lumen, the implant comprising: a body having a distal
end, a proximal end, and an axis therebetween, the distal end of
the body insertable through the punctum into the canalicular lumen,
the body comprising a therapeutic agent included within an agent
matrix drug core, exposure of the agent matrix to the tear fluid
effecting an effective therapeutic agent release into the tear
fluid over a sustained period, the body also having a sheath
disposed over the agent matrix to inhibit release of the agent away
from the proximal end and an outer surface configured to engage
luminal wall tissues so as to inhibit expulsion when disposed
therein.
2. The implant of claim 1, wherein the agent matrix comprises a
non-bioabsorbable polymer.
3. The implant of claim 2, wherein the agent matrix comprises
silicone in a non-homogenous mixture with the agent.
4. The implant of claim 3, wherein the non-homogenous mixture
comprises a silicone matrix portion that is saturated with the
therapeutic agent and an inclusions portion comprising inclusions
of the therapeutic agent.
5. The implant of claim 1, wherein the outer surface is disposed on
the sheath, and wherein the outer surface defines a body shape that
inhibits expulsion of the body from the punctum.
6. The implant of claim 1, wherein the body further comprises a
support structure over the agent matrix, the support structure
defining the outer surface and configured to inhibit expulsion of
the body from the punctum.
7. The implant of claim 6, wherein the support structure receives
the sheath and agent matrix drug core therein and inhibits
inadvertent expulsion of the agent matrix in use.
8. The implant of claim 6, wherein the support structure comprises
a helical coil.
9. The implant of claim 6, wherein the support structure has a
receptacle therein, and wherein the receptacle fittingly receives
the sheath and agent matrix therein so as to allow unrestricted
fluid communication between the proximal end and the tear film in
use.
10. The implant of claim 1, wherein the outer surface expands
radially when released within the punctum, and wherein the radial
expansion inhibits the expulsion from the punctum.
11. The implant of claim 1, wherein the agent comprises a
prostaglandin analogue, and wherein the extended period comprises
at least 3 months.
12. An implant for insertion into a patient, the patient having a
path for tear fluid associated with an eye, the implant comprising:
a body comprising a therapeutic agent and a support structure, the
body configured to, when implanted at a target location along the
tear fluid path, release a quantity of the therapeutic agent into
the tear fluid each day for a sustained release period of days, the
quantity being significantly less than 10% of a recommended daily
drop-administered quantity of the therapeutic agent.
13. The implant of claim 12, wherein the quantity is less than 5%
of the recommended drop-administered quantity.
14. The implant of claim 12, wherein the period comprises at least
three weeks.
15. The implant of claim 12, wherein the period comprises at least
three months.
16. The implant of claim 12, wherein the therapeutic agent
comprises Timolol maleate.
17. The implant of claim 12, wherein the therapeutic agent
comprises Latanoprost or another prostaglandin analogue.
18. The implant of claim 12, wherein the body comprises in a range
from about 270 .mu.g to about 1350 .mu.g of the therapeutic
agent.
19. The implant of claim 12, wherein the quantity is in a range
from about 20 .mu.g to about 135 .mu.g.
20. The implant of claim 12, wherein the body comprises therapeutic
agent in a range from about 3 .mu.g to about 135 .mu.g.
21. The implant of claim 20, wherein the therapeutic agent
comprises a prostaglandin analog.
22. The implant of claim 20, wherein the therapeutic agent
comprises latanoprost.
23. The implant of claim 20, wherein therapeutic agent comprises
bimatoprost.
24. The implant of claim 12, wherein the quantity is in a range
from about 5 ng to about 500 ng.
25. The implant of claim 12, wherein the body comprises therapeutic
agent in a range from about 5 .mu.g to about 30 .mu.g.
26. The implant of claim 12, wherein the quantity is in a range
from about 10 ng to about 150 ng.
27. A method of delivering a therapeutic agent to an eye having
associated tear fluid, the method comprising: placing a drug core
in a canaliculus of the eye, the drug core comprising a matrix and
inclusions of the therapeutic agent within the matrix, wherein a
portion of the drug core is exposed to the tear; releasing the
therapeutic agent to the tear of the eye, wherein the therapeutic
agent dissolves into the matrix such that the matrix remains
substantially saturated with the therapeutic agent while the
therapeutic agent is released through the exposed portion at
therapeutic levels over a sustained period.
28. The method of claim 27, wherein a rate of release is
substantially determined by solubility of the agent in the core,
solubility of the agent in the tear and an area of the exposed
portion.
29. The method of claim 27 wherein the drug is released through the
exposed portion at therapeutic levels for about 90 days.
30. The method of claim 27, wherein the therapeutic agent comprises
a prostaglandin analogue.
31. The method of claim 27, wherein the inclusions of the
therapeutic agent comprise an oil.
32. The method of claim 27, wherein the therapeutic agent is
encapsulated within the matrix and the matrix comprises a
non-bioabsorbable polymer.
33. The method of claim 27, wherein the therapeutic agent has a
solubility in water of less than about 0.03% percent by weight
34. The method of claim 27, wherein the therapeutic agent is
released at therapeutic levels in response to a surfactant of the
tear.
35. The method of claim 27, wherein a sheath is disposed over the
core to define the exposed portion, and the exposed portion is
oriented toward the eye on a proximal end of the core.
36. A punctal plug to treat glaucoma, the plug comprising: a body
no more than about 2.0 mm across, when inserted in the punctum for
35 days delivers at least a therapeutic quantity of therapeutic
agent each day of the 35 days.
37. The punctal plug of claim 36, wherein the body no more than
about 2.0 mm across comprises a cross sectional size no more than
about 1.0 mm across while inserted into the patient.
38. The punctal plug of claim 36, wherein the body comprises a drug
core and the therapeutic agent is delivered from the drug core, and
the drug core is no more than about 1 mm across.
39. The punctal plug of claim 36, wherein the body is no more than
about 2 mm in length.
40. A method of treating glaucoma with a punctal plug, the method
comprising: eluting at least 10 ng per day of a therapeutic agent
from the punctal plug for at least 90 days.
41. The method of claim 40, wherein the therapeutic agent comprises
at least one of Bimatoprost or Latanoprost.
42. The method of claim 40, wherein the therapeutic agent has a
solubility in water no more than about 0.03% by weight.
43. A punctal plug to treat glaucoma, the plug comprising: a plug
body, the body comprising a therapeutic agent, wherein the body is
adapted to release the therapeutic agent at therapeutic levels in
response to a surfactant of the eye.
44. The plug of claim 43 wherein the therapeutic agent has a
solubility in water no more than about 0.03% by weight.
45. The plug of claim 43 wherein the therapeutic agent comprises
cyclosporin.
46. A punctal plug to treat glaucoma, the plug comprising: a plug
body, the body comprising a therapeutic agent, wherein the body is
adapted to release from about 80 to 120 ng of the therapeutic agent
into a tear of the eye for at least about 20 days.
47. The punctal plug of claim 46 wherein the therapeutic agent
comprises at least one of Bimatoprost or Latanoprost.
48. A punctal plug to treat glaucoma, the punctal plug comprising:
a body comprising therapeutic agent stored within a volume no more
than about 0.02 cm.sup.3, wherein the body is adapted to deliver
therapeutic levels of the therapeutic agent for at least about 1
month.
49. The punctal plug of claim 48 wherein the body is adapted to
deliver the therapeutic agent at therapeutic levels for at least
about 3 months.
50. The punctal plug of claim 48 wherein the body is adapted to
deliver the therapeutic agent with a substantially zero order
release rate for the at least one month.
51. A composition of matter to treat glaucoma of an eye having an
associated tear, the composition comprising: inclusions comprising
a concentrated form of a therapeutic agent, wherein the therapeutic
agent comprises a solubility in water no more than about 0.03% by
weight; and a silicon matrix encapsulating the inclusions, wherein
the therapeutic agent is soluble in the silicone matrix to release
the therapeutic agent from the silicone matrix into the tear at
therapeutic levels.
52. The composition of claim 51 wherein the therapeutic agent
inclusions encapsulated within the silicon matrix comprise an
inhomogeneous mixture of the inclusions encapsulated within the
silicon matrix.
53. The composition of claim 51 wherein the inclusions comprise
Latanoprost oil.
Description
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 USC 119(e) of
U.S. Provisional Application No. 60/787,775 filed on Mar. 31, 2006,
and of U.S. Provisional Application No. 60/871,864, filed on Dec.
26, 2006, the full disclosures of which are incorporated herein by
reference.
BACKGROUND OF THE INVENTION
[0002] The present application is related to implants for use in or
near the nasolacrimal drainage system, with embodiments providing
canalicular implants, lacrimal sac implants, punctal plugs and
punctal plugs with drug delivery capabilities.
[0003] A variety of challenges face patients and physicians in the
area of ocular drug delivery. In particular, the repetitive nature
of the therapies (multiple injections, instilling multiple eye drop
regimens per day), the associated costs, and the lack of patient
compliance may significantly impact the efficacy of the therapies
available, leading to reduction in vision and many times
blindness.
[0004] Patient compliance in taking the medications, for example
instilling the eye drops, can be erratic, and in some cases,
patients may not follow the directed treatment regime. Lack of
compliance can include, failure to instill the drops, ineffective
technique (instilling less than required), excessive use of the
drops (leading to systemic side effects), and use of non-prescribed
drops or failure to follow the treatment regime requiring multiple
types of drops. Many of the medications may require the patient to
instill them up to 4 times a day.
[0005] In addition to compliance, the cost of at least some eye
drop medications is increasing, leading some patients on limited
incomes to be faced with the choice of buying basic necessities or
instead getting their prescriptions filled. Many times insurance
does not cover the total cost of the prescribed eye drop
medication, or in some cases eye drops containing multiple
different medications.
[0006] Further, in many cases, topically applied medications have a
peak ocular effect within about two hours, after which additional
applications of the medications should be performed to maintain the
therapeutic benefit. In addition, inconsistency in
self-administered or ingested medication regimes can result in a
suboptimal therapy. PCT Publication WO 06/014434 (Lazar), which is
incorporated herein by reference in its entirety, may be relevant
to these and/or other issues associated with eye drops.
[0007] One promising approach to ocular drug delivery is to place
an implant that releases a drug in tissue near the eye. Although
this approach can offer some improvement over eye drops, some
potential problems of this approach may include implantation of the
implant at the desire tissue location, retention of the implant at
the desired tissue location, and sustaining release of the drug at
the desired therapeutic level for an extended period of time. For
example in the case of glaucoma treatment, undetected and premature
loss of an implant can result in no drug being delivered, and the
patient can potentially suffer a reduction in vision, possibly even
blindness.
[0008] In light of the above, it would be desirable to provide
improved drug delivery implants that overcome at least some of the
above mentioned shortcomings.
BRIEF SUMMARY OF THE INVENTION
[0009] The present invention provides implant devices, systems and
methods for delivery of a therapeutic agent from a punctum of a
patient ocular tissues.
[0010] In a first aspect, embodiments of the present invention
provide an implant for insertion into a punctum of a patient. The
punctum provides a flow path for a tear fluid from an eye to a
canalicular lumen. The implant comprises a body. The body has a
distal end, a proximal end, and an axis therebetween. The distal
end of the body is insertable distally through the punctum into the
canalicular lumen. The body comprises a therapeutic agent included
within an agent matrix drug core. Exposure of the agent matrix to
the tear fluid effects an effective therapeutic agent release into
the tear fluid over a sustained period. The body has a sheath
disposed over the agent matrix to inhibit release of the agent away
from the proximal end. The body also has an outer surface
configured to engage luminal wall tissues so as to inhibit
expulsion when disposed therein.
[0011] In some embodiments, the agent matrix comprises a
non-bioabsorbable polymer, for example silicone in a non-homogenous
mixture with the agent. The non-homogeneous mixture may comprise a
silicone matrix saturated with the therapeutic agent and inclusions
of the therapeutic agent.
[0012] In many embodiments, the outer surface of the body can be
disposed on the sheath, and the outer surface may define a body
shape that inhibits expulsion of the body from the punctum. The
body may further comprise a support structure over the agent
matrix. The support structure may define the outer surface and be
configured to inhibit expulsion of the body from the punctum. In
specific embodiments, the support structure receives the sheath and
agent matrix drug core therein, and inhibits inadvertent expulsion
of the agent matrix in use. The support structure can comprise a
helical coil. The support structure may have a receptacle therein,
and the receptacle may fittingly receive the sheath and agent
matrix therein so as to allow unrestricted fluid communication
between the proximal end and the tear film in use. The outer
surface may expand radially when released within the punctum, and
the radial expansion may inhibits the expulsion from the
punctum.
[0013] In specific embodiments, the agent comprises a prostaglandin
analogue, and the extended period comprises at least 3 months.
[0014] In many embodiments, an implant for insertion into a patient
is provided. The patient having path for tear fluid associated with
an eye, and the implant comprises a body. The body can comprise a
therapeutic agent and a support structure. The body can be
configured to, when implanted at a target location along the tear
fluid path, release a quantity of the therapeutic agent into the
tear fluid each day for a sustained release period of days. The
quantity can be significantly less than a recommended daily
drop-administered quantity of the therapeutic agent. For example,
the quantity can be less than 10% of the recommended
drop-administered quantity. In specific embodiments, the quantity
can be less than 5% of the recommended drop-administered
quantity.
[0015] In many embodiments, the period comprises at least three
weeks and may comprise at least three months. The therapeutic agent
may comprise Timolol maleate. The body may comprise in a range from
about 270 .mu.g to about 1350 .mu.g of the therapeutic agent. The
quantity released each day can be in a range from about 20 .mu.g to
about 135 .mu.g.
[0016] In many embodiments, the therapeutic agent may comprise a
prostaglandin analogue, for example Latanoprost and/or Bimatoprost,
and the body can comprise therapeutic agent in a range from about 3
.mu.g to about 135 .mu.g. The quantity can be in a range from about
5 ng to about 500 ng. In specific embodiments, the body may
comprise therapeutic agent in a range from about 5 .mu.g to about
30 .mu.g, and the quantity can be in a range from about 10 ng to
150 ng.
[0017] In another aspect, embodiments of the present invention
provide a method of delivering a therapeutic agent to an eye having
associated tear fluid. The method comprises placing a drug core in
a canaliculus of the eye. The drug core comprises a matrix and
inclusions of the therapeutic agent within the matrix. A portion of
the drug core is exposed to the tear. The therapeutic agent is
released to the tear of the eye. The therapeutic agent dissolves
into the matrix such that the matrix remains substantially
saturated with the therapeutic agent while the therapeutic agent is
released through the exposed portion at therapeutic levels over a
sustained period.
[0018] In many embodiments, a rate of release is substantially
determined by solubility of the agent in the core, the solubility
of the agent in the tear and an area of the exposed portion. The
drug can be released through the exposed portion at therapeutic
levels for about 90 days. The therapeutic agent may comprise a
prostaglandin analogue, and the inclusions of the therapeutic agent
comprise an oil. The therapeutic agent can be encapsulated within
the matrix, and the matrix may comprise a non-bioabsorbable
polymer.
[0019] In many embodiments, the therapeutic agent has a solubility
in water of less than about 0.03% percent by weight. The
therapeutic agent can be released at therapeutic levels in response
to a surfactant of the tear. A sheath may be disposed over the core
to define the exposed portion, and the exposed portion oriented
toward the eye on a proximal end of the core.
[0020] In many embodiments, a punctal plug to treat glaucoma is
provided. The plug comprises a body no more than about 2.0 mm
across. When inserted in the punctum for 35 days the body delivers
at least a therapeutic quantity of therapeutic agent each day of
the 35 days. In some embodiments, the body no more than about 2.0
mm across comprises a cross sectional size no more than about 1.0
mm across while inserted into the patient. In specific embodiments,
the body comprises a drug core and the therapeutic agent is
delivered from the drug core. The drug core may be no more than
about 1 mm across, and the body may be no more than about 2 mm in
length.
[0021] In many embodiments, a method of treating glaucoma is
provided with a punctal plug, The method comprises eluting at least
10 ng per day of a therapeutic agent from the punctal plug for at
least 90 days. In specific embodiments, the therapeutic agent
comprises at least one of Bimatoprost or Latanoprost. The
therapeutic agent may have a solubility in water no more than about
0.03% by weight.
[0022] In many embodiments, a punctal plug to treat glaucoma is
provided, the plug comprises a body. The body comprises a
therapeutic agent, and the body is adapted to release the
therapeutic agent at therapeutic levels in response to a surfactant
of the eye. In specific embodiments, the therapeutic agent has a
solubility in water no more than about 0.03% by weight. The
therapeutic agent may comprise cyclosporin.
[0023] In many embodiments, a punctal plug to treat glaucoma is
provided. The plug comprises a plug body. The body comprises a
therapeutic agent. The body is adapted to release from about 80 to
120 ng of the therapeutic agent into a tear of the eye for at least
about 20 days. In specific embodiments, the therapeutic agent may
comprise at least one of Bimatoprost or Latanoprost.
[0024] In some embodiments, a punctal plug to treat glaucoma is
provided. The punctal plug comprises a body. The body comprises
therapeutic agent stored within a volume no more than about 0.02
cm.sup.3. The body is adapted to deliver therapeutic levels of the
therapeutic agent for at least about 1 month. In specific
embodiments, the body is adapted to deliver the therapeutic agent
at therapeutic levels for at least about 3 months. The body can be
adapted to deliver the therapeutic agent with a substantially zero
order release rate for the at least one month.
[0025] In some embodiments, composition of matter to treat glaucoma
of an eye having an associated tear is provided. The composition
comprises inclusions. The inclusions comprise a concentrated form
of a therapeutic agent. The therapeutic agent comprises a
solubility in water no more than about 0.03% by weight. A silicone
matrix encapsulates the inclusions. The therapeutic agent is
soluble in the silicone matrix to release the therapeutic agent
from the silicon matrix into the tear at therapeutic levels. In
specific embodiments, the therapeutic agent inclusions are
encapsulated within the silicon matrix comprise an inhomogeneous
mixture of the inclusions encapsulated within the silicon matrix.
The inclusions can comprise Latanoprost oil.
BRIEF DESCRIPTION OF THE DRAWINGS
[0026] FIGS. 1-1 and 1-2 show anatomical tissue structures of the
eye suitable for use with implants, according to embodiments of the
present invention;
[0027] FIG. 1A shows a top cross sectional view of a sustained
release implant to treat an optical defect of an eye, according to
an embodiment of the present invention;
[0028] FIG. 1B shows a side cross sectional view of the sustained
release implant of FIG. 1A;
[0029] FIG. 1C shows a perspective view of a sustained release
implant with a coil retention structure, according to an embodiment
of the present invention;
[0030] FIG. 1D shows a perspective view of a sustained release
implant with a retention structure comprising struts, according to
an embodiment of the present invention;
[0031] FIG. 1E shows a perspective view of a sustained release
implant with a cage retention structure, according to an embodiment
of the present invention;
[0032] FIG. 1F shows a perspective view of a sustained release
implant comprising a core and sheath, according to an embodiment of
the present invention;
[0033] FIG. 1G schematically illustrates a sustained release
implant comprising a flow restricting retention element, a core and
a sheath, according to an embodiment of the present invention;
[0034] FIG. 2A shows a cross sectional view of a sustained release
implant with core comprising an enlarged exposed surface area,
according to an embodiment of the present invention;
[0035] FIG. 2B shows a cross sectional view of a sustained release
implant with a core comprising an enlarged exposed surface area,
according to an embodiment of the present invention;
[0036] FIGS. 2C and 2D show perspective view and cross sectional
views, respectively, of a sustained release implant with a core
comprising a reduced exposed surface area, according to an
embodiment of the present invention;
[0037] FIG. 2E shows a cross sectional view of a sustained release
implant with a core comprising an enlarged exposed surface area
with an indentation and castellation, according to an embodiment of
the present invention;
[0038] FIG. 2F shows a perspective view of a sustained release
implant comprising a core with folds, according to an embodiment of
the present invention;
[0039] FIG. 2G shows a perspective view of a sustained release
implant with a core comprising a channel with an internal porous
surface, according to an embodiment of the present invention;
[0040] FIG. 2H shows a perspective view of a sustained release
implant with a core comprising porous channels to increase drug
migration, according to an embodiment of the invention;
[0041] FIG. 2I shows a perspective view of a sustained release
implant with a convex exposed drug core surface, according to an
embodiment of the present invention;
[0042] FIG. 2J shows a side view of a sustained release implant
with a core comprising an exposed surface area with several soft
brush-like members extending therefrom, according to an embodiment
of the present invention;
[0043] FIG. 2K shows a side view of a sustained release implant
with a drug core comprising a convex exposed surface and a
retention structure, according to an embodiment of the present
invention;
[0044] FIG. 2L shows a side view of a sustained release implant
with a drug core comprising a concave indented surface to increase
exposed surface area of the core, according to an embodiment of the
present invention;
[0045] FIG. 2M shows a side view of a sustained release implant
with a drug core comprising a concave surface with a channel formed
therein to increase an exposed surface area of the core, according
to an embodiment of the present invention;
[0046] FIG. 3A shows an implant with a sheath body with extensions
that attach the sheath body and core to the retention element,
according to an embodiment of the present invention;
[0047] FIG. 3B shows an implant with a retention element with an
extension that retains a sheath body and a core, according to an
embodiment of the present invention;
[0048] FIGS. 4A and 4B show a cross-sectional view of an implant
with a retention structure that is shorter in length while in a
large cross-sectional profile configuration than a small
cross-sectional profile configuration, according to an embodiment
of the present invention;
[0049] FIGS. 5A to 5C schematically illustrate replacement of a
drug core and a sheath body, according to an embodiment of the
present invention;
[0050] FIGS. 6A to 6C show deployment of a sustained release
implant, according to an embodiment of the present invention;
and
[0051] FIGS. 7A and 7B show elution data of Latanoprost at day 1
and day 14, respectively, for the three core diameters of 0.006,
0.012 and 0.025 inches and three Latanoprost concentrations of
approximately 5%, 11% and 18%, according to embodiments of the
present invention;
[0052] FIG. 7C shows elution data for Latanoprost from 0.32 mm
diameter, 0.95 mm long drug cores with concentrations of 5, 10 and
20% and drug weights of 3.5, 7 and 14 .mu.g, respectively,
according to embodiments of the present invention;
[0053] FIGS. 7D and 7E show dependence of the rate of elution on
exposed surface area of the drug core for the three core diameters
and the three concentrations as in FIGS. 7A and 7B Latanoprost at
day 1 and day 14, respectively, according to embodiments of the
present invention;
[0054] FIG. 8A shows elution profiles of cyclosporine from drug
cores into a buffer solution with surfactant and a buffer solution
with surfactant, according to embodiments of the present
invention;
[0055] FIG. 9A shows normalized elution profiles in nano-grams per
device per day over 100 days for bulk sample of silicone with 1%
Bimatoprost, according to embodiments of the present invention.
[0056] FIG. 10A shows profiles of elution of Latanoprost from the
cores for four formulations of Latanoprost according to embodiments
of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0057] FIGS. 1-1 and 1-2 show anatomical tissue structures of an
eye 2 suitable for treatment with implants, according to an
embodiment of the present invention. Eye 2 includes a cornea 4 and
an iris 6. A sclera 8 surrounds cornea 4 and iris 6 and appears
white. A conjunctival layer 9 is substantially transparent and
disposed over sclera 8. A crystalline lens 5 is located within the
eye. A retina 7 is located near the back of eye 2 and is generally
sensitive to light. Retina 7 includes a fovea 7F that provides high
visual acuity and color vision. Cornea 4 and lens 5 refract light
to form an image on fovea 7F and retina 7. The optical power of
cornea 4 and lens 5 contribute to the formation of images on fovea
7F and retina 7. The relative locations of cornea 4, lens 5 and
fovea 7F are also important to image quality. For example, if the
axial length of eye 2 from cornea 4 to retina 7F is large, eye 2
can be myopic. Also, during accommodation, lens 5 moves toward
cornea 4 to provide good near vision of objects proximal to the
eye.
[0058] The anatomical tissue structures shown in FIG. 1-1 also
include the lacrimal system, which includes an upper canaliculus 10
and a lower canaliculus 12, collectively the canaliculae, and the
naso-lacrimal duct or sac 14. The upper and lower canaliculae
terminate in an upper punctum 11 and a lower punctum 13, also
referred to as punctal apertures. The punctal apertures are
situated on a slight elevation at the medial end of the lid margin
at the junction 15 of the ciliary and lacrimal portions near the
medial canthus 17. The punctal apertures are round or slightly
ovoid openings surrounded by a connective ring of tissue. Each of
the punctal openings 11, 13 leads into a vertical portion 10a, 12a
of the respective canaliculus before turning horizontally to join
its other canaliculus at the entrance of a lacrimal sac 14. The
canaliculae are tubular and lined by stratified squamous epithelium
surrounded by elastic tissue which permits the canaliculus to be
dilated.
[0059] FIG. 1A shows a top cross sectional view of a sustained
release implant 100 to treat an optical defect of an eye, according
to embodiments of the present invention. Implant 100 includes a
drug core 110. Drug core 110 is an implantable structure that
retains a therapeutic agent. Drug core 110 comprises a matrix 170
that contains inclusions 160 of therapeutic agent. Inclusions 160
will often comprise a concentrated form of the therapeutic agent,
for example a crystalline form of the therapeutic agent, and the
therapeutic agent may over time dissolve into matrix 170 of drug
core 110. Matrix 170 can comprise a silicone matrix or the like,
and the mixture of therapeutic agent within matrix 170 can be
non-homogeneous. In many embodiments, the non-homogenous mixture
comprises a silicone matrix portion that is saturated with the
therapeutic agent and an inclusions portion comprising inclusions
of the therapeutic agent, such that the non-homogenous mixture
comprises a multiphase non-homogenous mixture. In some embodiments,
inclusions 160 comprise droplets of an oil of the therapeutic
agent, for example Latanoprost oil. In some embodiments, inclusions
160 may comprise particles of the therapeutic agent, for example
solid Bimatoprost particles in crystalline form. In many
embodiments, matrix 170 encapsulates inclusions 160, and inclusions
160 may comprise microparticles have dimensions from about 1 .mu.m
to about 100 .mu.m. The encapsulated inclusions dissolve into the
surrounding solid matrix, for example silicone, that encapsulates
the micro particles such that matrix 170 is substantially saturated
with the therapeutic agent while the therapeutic agent is released
from the core.
[0060] Drug core 110 is surrounded by a sheath body 120. Sheath
body 120 is can be substantially impermeable to the therapeutic
agent, so that the therapeutic agent is often released from an
exposed surface on an end of drug core 110 that is not covered with
sheath body 120. A retention structure 130 is connected to drug
core 110 and sheath body 120. Retention structure 130 is shaped to
retain the implant in a hollow tissue structure, for example, a
punctum of a canaliculus as described above.
[0061] An occlusive element 140 is disposed on and around retention
structure 130. Occlusive element 140 is impermeable to tear flow
and occludes the hollow tissue structure and may also serve to
protect tissues of the tissue structure from retention structure
130 by providing a more benign tissue-engaging surface. Sheath body
120 includes a sheath body portion 150 that connects to retention
structure 130 to retain sheath body 120 and drug core 110. Sheath
body portion 150 can include a stop to limit movement of sheath
body 120 and drug core 110. In many embodiments, sheath body
portion 150 can be formed with a bulbous tip 150B. Bulbous tip 150B
can comprise a convex rounded external portion that provides
atraumatic entry upon introduction into the canaliculus. In many
embodiments, sheath body portion 150B can be integral with
occlusive element 140.
[0062] FIG. 1B shows a side cross sectional view of the sustained
release implant of FIG. 1A. Drug core 110 is cylindrical and shown
with a circular cross-section. Sheath body 120 comprises an annular
portion disposed on drug core 110. Retention structure 130
comprises several longitudinal struts 131. Longitudinal struts 131
are connected together near the ends of the retention structure.
Although longitudinal struts are shown, circumferential struts can
also be used. Occlusive element 140 is supported by and disposed
over longitudinal struts 131 of retention structure 130 and may
comprise a radially expandable membrane or the like.
[0063] FIG. 1C shows a perspective view of a sustained release
implant 102 with a coil retention structure 132, according to an
embodiment of the present invention. Retention structure 132
comprises a coil and retains a drug core 112. A lumen, for example
channel 112C, may extend through the drug core 112 to permit tear
flow through the lumen for the delivery of therapeutic agent for
nasal and systemic applications of the therapeutic agent. In
addition or in combination with channel 112C, retention structure
132 and core 112 can be sized to permit tear flow around the drug
core and sheath body while the retention element holds tissue of
the canaliculus away from the drug core. Drug core 112 may be
partially covered. The sheath body comprises a first component 122A
that covers a first end of drug cove 112 and a second component
122B that covers a second end of the drug core. An occlusive
element can be placed over the retention structure and/or the
retention structure can be dip coated as described above.
[0064] FIG. 1D shows a perspective view of a sustained release
implant 104 with a retention structure 134 comprising struts,
according to an embodiment of the present invention. Retention
structure 134 comprises longitudinal struts and retains a drug core
114. Drug core 114 is covered with a sheath body 124 over most of
drug core 114. The drug core releases therapeutic agent through an
exposed end and sheath body 124 is annular over most of the drug
core as described above. An occlusive element can be placed over
the retention structure or the retention structure can be dip
coated as described above. A protrusion that can be engaged with an
instrument, for example a hook, a loop, a suture, or ring 124R, can
extend from sheath body 124 to permit removal of the drug core and
sheath body together so as to facilitate replacement of the sheath
body and drug core while the retention structure remains implanted
in the canaliculus. In some embodiments, a protrusion that can be
engaged with an instrument comprising hook, a loop, a suture or a
ring, can extend from retention structure 134 to permit removal of
the sustained release implant by removing the retention structure
with the protrusion, drug core and sheath body.
[0065] FIG. 1E shows a perspective view of a sustained release
implant 106 with a cage retention structure 136, according to an
embodiment of the present invention. Retention structure 136
comprises several connected strands of metal and retains a drug
core 116. Drug core 116 is covered with a sheath body 126 over most
of drug core 116. The drug core releases therapeutic agent through
an exposed end and sheath body 126 is annular over most of the drug
core as described above. An occlusive element can be placed over
the retention structure or the retention structure can be dip
coated as described above.
[0066] FIG. 1F shows a perspective view of a sustained release
implant comprising a core and sheath, according to an embodiment of
the present invention. Drug core 118 is covered with a sheath body
128 over most of drug core 118. The drug core releases therapeutic
agent through an exposed end and sheath body 128 is annular over
most of the drug core as described above. The rate of therapeutic
agent release is controlled by the surface area of the exposed drug
core and materials included within drug core 118. In many
embodiments, the rate of elution of the therapeutic agent is
strongly and substantially related to the exposed surface area of
the drug core and weakly dependent on the concentration of drug
disposed in the inclusions in the drug core. For circular exposed
surfaces the rate of elution is strongly dependent on the diameter
of the exposed surface, for example the diameter of an exposed drug
core surface near an end of a cylindrical drug core. Such an
implant can be implanted in ocular tissues, for example below
conjunctival tissue layer 9 of the eye and either above sclera
tissue layer 8, as shown in FIG. 1F, or only partially within the
scleral tissue layer so as not to penetrate the scleral tissue. It
should be noted that drug core 118 can be used with any of the
retention structures and occlusive elements as described
herein.
[0067] In an embodiment, the drug core is implanted between sclera
8 and conjunctiva 9 without sheath body 128. In this embodiment
without the sheath body, the physical characteristics of the drug
core can be adjusted to compensate for the increased exposed
surface of drug core, for example by reducing the concentration of
dissolved therapeutic agent in the drug core matrix as described
herein.
[0068] FIG. 1G schematically illustrates a sustained release
implant 180 comprising a flow restricting retention structure 186,
a core 182 and a sheath 184, according to an embodiment of the
present invention. Sheath body 184 can at least partially cover
drug core 182. Drug core 182 may contain inclusions of the
therapeutic agent therein to provide a sustained release of the
therapeutic agent. Drug core 182 can include an exposed convex
surface area 182A. Exposed convex surface area 182A may provide an
increased surface area to release the therapeutic agent. An
occlusive element 188 can be disposed over retention structure 186
to block the flow of tear through the canaliculus. In many
embodiments, retention structure 186 can be located within
occlusive structure 188 to provide the occlusive element integrated
with the retention structure. Flow restricting retention structure
186 and occlusive element 188 can be sized to block tear flow
through the canaliculus.
[0069] The cores and sheath bodies described herein can be
implanted in a variety of tissues in several ways. Many of the
cores and sheaths described herein, in particular the structures
described with reference to FIGS. 2A to 2J can be implanted alone
as punctal plugs. Alternatively, many of the cores and sheath
bodies described herein can comprise a drug core, sheath body,
and/or the like so as to be implanted with the retention structures
and occlusive elements described herein.
[0070] FIG. 2A shows a cross sectional view of a sustained release
implant 200 with core comprising an enlarged exposed surface area,
according to an embodiment of the present invention. A drug core
210 is covered with a sheath body 220. Sheath body 220 includes an
opening 220A. Opening 220 has a diameter that approximates the
maximum cross sectional diameter of drug core 210. Drug core 210
includes an exposed surface 210E, also referred to as an active
surface. Exposed surface 210E includes 3 surfaces: an annular
surface 210A, a cylindrical surface 210B and an end surface 210C.
Annular surface 210A has an outer diameter that approximates the
maximum cross sectional diameter of core 210 and an inner diameter
that approximates the outer diameter of cylindrical surface 210B.
End surface 210C has a diameter that matches the diameter of
cylindrical surface 210B. The surface area of exposed surface 210E
is the sum of the areas of annular surface 210A, cylindrical
surface 210B and end surface 210C. The surface area may be
increased by the size of cylindrical surface area 210B that extends
longitudinally along an axis of core 210.
[0071] FIG. 2B shows a cross sectional view of a sustained release
implant 202 with a core 212 comprising an enlarged exposed surface
area 212A, according to an embodiment of the present invention. A
sheath body 222 extends over core 212. The treatment agent can be
released from the core as described above. Exposed surface area
212A is approximately conical, can be ellipsoidal or spherical, and
extends outward from the sheath body to increase the exposed
surface area of drug core 212.
[0072] FIGS. 2C and 2D show perspective and cross sectional views,
respectively, of a sustained release implant 204 with a drug core
214 comprising a reduced exposed surface area 214A, according to an
embodiment of the present invention. Drug core 214 is enclosed
within a sheath body 224. Sheath body 22 includes an annular end
portion 224A that defines an opening through which drug core 214
extends. Drug core 214 includes an exposed surface 214A that
releases the therapeutic agent. Exposed surface 214A has a diameter
214D that is less than a maximum dimension, for example a maximum
diameter, across drug core 214.
[0073] FIG. 2E shows a cross sectional view of a sustained release
implant 206 with a drug core 216 comprising an enlarged exposed
surface area 216A with castellation extending therefrom, according
to an embodiment of the present invention. The castellation
includes several spaced apart fingers 216F to provide increased
surface area of the exposed surface 216A. In addition to increased
surface area provided by castellation, drug core 216 may also
include an indentation 2161. Indentation 2161 may have the shape of
an inverted cone. Core 216 is covered with a sheath body 226.
Sheath body 226 is open on one end to provide an exposed surface
216A on drug core 216. Sheath body 226 also includes fingers and
has a castellation pattern that matches core 216.
[0074] FIG. 2F shows a perspective view of a sustained release
implant 250 comprising a core with folds, according to an
embodiment of the present invention. Implant 250 includes a core
260 and a sheath body 270. Core 260 has an exposed surface 260A on
the end of the core that permits drug migration to the surrounding
tear or tear film fluid. Core 260 also includes folds 260F. Folds
260F increase the surface area of core that is exposed to the
surrounding fluid tear or tear film fluid. With this increase in
exposed surface area, folds 260F increase migration of the
therapeutic agent from core 260 into the tear or tear film fluid
and target treatment area. Folds 260F are formed so that a channel
260C is formed in core 260. Channel 260C connects to the end of the
core to an opening in exposed surface 260A and provides for the
migration of treatment agent. Thus, the total exposed surface area
of core 260 includes exposed surface 260A that is directly exposed
to the tear or tear film fluid and the surfaces of folds 260F that
are exposed to the tear or tear film fluids via connection of
channel 260C with exposed surface 260A and the tear or tear film
fluid.
[0075] FIG. 2G shows a perspective view of a sustained release
implant with a core comprising a channel with an internal porous
surface, according to an embodiment of the present invention.
Implant 252 includes a core 262 and sheath body 272. Core 262 has
an exposed surface 262A on the end of the core that permits drug
migration to the surrounding tear or tear film fluid. Core 262 also
includes a channel 262C. Channel 262C increases the surface area of
the channel with a porous internal surface 262P formed on the
inside of the channel against the core. Channel 262C extends to the
end of the core near exposed surface 262A of the core. The surface
area of core that is exposed to the surrounding tear or tear film
fluid can include the inside of core 262 that is exposed to channel
262C. This increase in exposed surface area can increase migration
of the therapeutic agent from core 262 into the tear or tear film
fluid and target treatment area. Thus, the total exposed surface
area of core 262 can include exposed surface 260A that is directly
exposed to the tear or tear film fluid and porous internal surface
262P that is exposed to the tear or tear film fluids via connection
of channel 262C with exposed surface 262A and the tear or tear film
fluid.
[0076] FIG. 2H shows a perspective view of a sustained release
implant 254 with a core 264 comprising channels to increase drug
migration, according to an embodiment of the invention. Implant 254
includes core 264 and sheath body 274. Exposed surface 264A is
located on the end of core 264, although the exposed surface can be
positioned at other locations. Exposed surface 264A permits drug
migration to the surrounding tear or tear film fluid. Core 264 also
includes channels 264C. Channels 264C extend to exposed surface
264. Channels 264C are large enough that tear or tear film fluid
can enter the channels and therefore increase the surface area of
core 264 that is in contact with tear or tear film fluid. The
surface area of the core that is exposed to the surrounding fluid
tear or tear film fluid includes the inner surfaces 264P of core
262 that define channels 264C. With this increase in exposed
surface area, channels 264C increase migration of the therapeutic
agent from core 264 into the tear or tear film fluid and target
treatment area. Thus, the total exposed surface area of core 264
includes exposed surface 264A that is directly exposed to the tear
or tear film fluid and internal surface 264P that is exposed to the
tear or tear film fluids via connection of channels 262C with
exposed surface 264A and the tear or tear film fluid.
[0077] FIG. 2I shows a perspective view of a sustained release
implant 256 with a drug core 266 comprising a convex exposed
surface 266A, according to an embodiment of the present invention.
Drug core 266 is partially covered with a sheath body 276 that
extends at least partially over drug core 266 to define convex
exposed surface 266A. Sheath body 276 comprises a shaft portion
276S. Convex exposed surface 266A provides an increased exposed
surface area above the sheath body. A cross sectional area of
convex exposed surface 266A is larger than a cross sectional area
of shaft portion 276S of sheath body 276. In addition to the larger
cross sectional area, convex exposed surface 266A has a larger
surface area due to the convex shape which extends outward from the
core. Sheath body 276 comprises several fingers 276F that support
drug core 266 in the sheath body and provide support to the drug
core to hold drug core 266 in place in sheath body 276. Fingers
276F are spaced apart to permit drug migration from the core to the
tear or tear film fluid between the fingers. Protrusions 276P
extend outward on sheath body 276. Protrusions 276P can be pressed
inward to eject drug core 266 from sheath body 276. Drug core 266
can be replaced with another drug core after an appropriate time,
for example after drug core 266 has released most of the
therapeutic agent.
[0078] FIG. 2J shows a side view of a sustained release implant 258
with a core 268 comprising an exposed surface area with several
soft brush-like members 268F, according to an embodiment of the
present invention. Drug core 268 is partially covered with a sheath
body 278 that extends at least partially over drug core 268 to
define exposed surface 268A. Sheath body 278 comprises a shaft
portion 278S. Soft brush-like members 268F extend outward from drug
core 268 and provide an increased exposed surface area to drug core
268. Soft brush-like members 268F are also soft and resilient and
easily deflected such that these members do not cause irritation to
neighboring tissue. Although drug core 268 can be made of many
materials as explained above, silicone is a suitable material for
the manufacture of drug core 268 comprises soft brush like members
268F. Exposed surface 268A of drug core 268 also includes an
indentation 2681 such that at least a portion of exposed surface
268A is concave.
[0079] FIG. 2K shows a side view of a sustained release implant 259
with a drug core 269 comprising a convex exposed surface 269A,
according to an embodiment of the present invention. Drug core 269
is partially covered with a sheath body 279 that extends at least
partially over drug core 269 to define convex exposed surface 269A.
Sheath body 279 comprises a shaft portion 279S. Convex exposed
surface 269 provides an increased exposed surface area above the
sheath body. A cross sectional area of convex exposed surface 269A
is larger than a cross sectional area of shaft portion 279S of
sheath body 279. In addition to the larger cross sectional area,
convex exposed surface 269A has a larger surface area due to the
convex shape that extends outward on the core. A retention
structure 289 can be attached to sheath body 279. Retention
structure 289 can comprise any of the retention structures as
describe herein, for example a coil comprising a super elastic
shape memory alloy such as Nitinol.TM.. Retention structure 289 can
be dip coated to make retention structure 289 biocompatible.
[0080] FIG. 2L shows a side view of a sustained release implant 230
with a drug core 232 comprising a concave indented surface 232A to
increase exposed surface area of the core, according to an
embodiment of the present invention. A sheath body 234 extends at
least partially over drug core 232. Concave indented surface 232A
is formed on an exposed end of drug core 232 to provide an
increased exposed surface area of the drug core.
[0081] FIG. 2M shows a side view of a sustained release implant 240
with a drug core 242 comprising a concave surface 242A with a
channel 242C formed therein to increase an exposed surface area of
the core, according to an embodiment of the present invention. A
sheath body 244 extends at least partially over drug core 242.
Concave indented surface 242A is formed on an exposed end of drug
core 232 to provide an increased exposed surface area of the drug
core. Channel 242C formed in drug core 242 to provide an increased
exposed surface area of the drug core. Channel 242C can extend to
concave indented surface 242A such that channel 242C and provide an
increase in surface area of the core exposed to the tear or tear
film film.
[0082] FIG. 3A shows an implant 310 comprising a sheath body 320
with extensions 322, according to an embodiment of the present
invention. Extensions 322 attach sheath body 320 to the retention
element to retain the core near the punctum. Sheath body 320
extends over core 330 to define an exposed surface 332 of core 330.
Extensions 322 can be resilient and engage the retention element
and/or occlusive element to attach the sheath body core to the
retention element to retain the core near the punctum.
[0083] FIG. 3B shows an implant 350 comprising a retention element
380 with an extension 382, according to an embodiment of the
present invention. Extension 382 retains a sheath body 360 and a
core 370. Sheath body 360 extends over core 370 to define an
exposed surface 372 of core 370. Exposed surface 372 is disposed
near the proximal end of core 370. Extension 382 extends downward
to retain core 370 and sheath body 370.
[0084] FIGS. 4A and 4B show a cross-sectional view of an implant
400 with a retention structure 430 that is shorter in length while
in a large cross-sectional profile configuration than a small
cross-sectional profile configuration, according to an embodiment
of the present invention. Implant 400 includes a distal end 402 and
a proximal end 404. Implant 400 includes a drug core 410 and a
sheath body 420. Sheath body 420 at least partially covers drug
core 410 and defines an exposed surface 412 of drug core 410. An
occlusive element 440 can be attached to and supported by retention
structure 430. Occlusive element 440 can move with retention
structure 430, for example when retention element 430 expands from
a small profile configuration to a large profile configuration. In
many embodiments, the retention structure and occlusive element are
sized to correspond to a diameter of the canaliculus, for example
to match a diameter of the canaliculus or slightly larger than the
canalicular diameter, so as occlude fluid flow through the
canaliculus and/or anchor in the canaliculus.
[0085] As shown in FIG. 4A, retention structure 430 and occlusive
element 440 are in a small profile configuration. Such a small
profile configuration can occur while the occlusive element and
retention structure are placed in a tip of an insertion tool and
covered for deployment. Retention element 430 and occlusive element
440 extend fully along the length of sheath body 420 and drug core
410. Retention element 430 is attached to sheath body 420 near
distal end 402. In many embodiments, retention structure 430 and
occlusive element 440 have diameters that are sized to fit inside
and slide within the canaliculus while in the small profile
configuration, and the retention structure and occlusive element
can be sized to anchor within the canaliculus while in a second
large profile configuration.
[0086] As shown in FIG. 4B, retention structure 430 and occlusive
element 440 are in a large profile configuration. Such a large
profile configuration can occur when the occlusive element and
retention structure are placed in the canaliculus. In the large
profile configuration, the length of occlusive element 440 and
retention structure 430 is shorter than in the small profile
configuration by a distance 450. The proximal end of retention
structure 430 and occlusive element 440 can slide over sheath body
420 when the sheath body and retention structure assume the large
profile configuration such that the proximal end of drug core 410
and sheath body 420 extend from the retention structure and
occlusive element. In some embodiments, the sheath body is shorter
than drug core 410 by distance 450 so that more of the drug core is
exposed while the retention structure and occlusive element are in
the large profile configuration than is exposed while the retention
structure and occlusive element are in the small profile
configuration. In such embodiments, the retention structure and
occlusive element retract to expose the drug core.
[0087] FIGS. 5A to 6 show embodiments of tools that can be used to
insert many of the implants as describe herein.
[0088] FIG. 5A shows an insertion tool 500 to insert an implant
into the punctum with a plunger 530 that can be depressed,
according to an embodiment of the present invention. Insertion tool
500 includes a dilator 510 that can be inserted into the punctum to
pre-dilate the punctum prior to insertion of an implant. An implant
520 can be pre-loaded onto tool 500 prior to dilation of the
punctum. An internal wire 540 can be connected to implant 520 to
retain the implant. Following pre-dilation of the punctum with
dilator 510, tool 500 can be used to insert implant 520 into the
punctum. While implant 520 is positioned in the punctum, plunger
530 can be depressed to engage wire 540 and release implant 520
from tool 500.
[0089] FIG. 5B shows an insertion tool 550 to insert an implant 570
into the punctum with a plunger that can slide, according to an
embodiment of the present invention. Insertion tool 550 includes a
dilator 560 with a conical section to dilate the punctum. Implant
550 includes a plunger 580 that can slide distally to advance
implant 570 into the lumen. A shaft 590 is connected to plunger 580
to advance implant 570 distally when plunger 580 is advanced
distally. While the punctum is dilated with dilator 560, plunger
580 can be advanced distally to place implant 570 in the
canalicular lumen near the punctum. In many embodiments, a button
can be depressed to advance distally the implant into the lumen,
for example a button connected to shaft 590 with an intermediate
mechanism.
[0090] FIG. 6 shows an insertion tool 600 to insert an implant into
the punctum with a sheath 610 that retracts to position the implant
in the canalicular lumen, according to an embodiment of the present
invention. At least a portion of sheath 610 is shaped to dilate the
punctum. Sheath 610 is shaped to hold an implant 620 in a small
profile configuration. Insertion tool 600 includes an annular
structure 615, which can comprise a portion of a body 605 of
insertion tool 600. Sheath 610 and annular structure 615 are shaped
to dilate the punctum and often comprise proximally inclined
surfaces to dilate the punctum. Implant 620, sheath 610 and annular
structure 615 can be at least partially inserted into the punctum
to place the implant in the canalicular lumen. Annular structure
615 is disposed over sheath 610 so that sheath 610 can be retracted
and slide under annular structure 615. A stop 625 can be connected
to body 605 to retain implant 620 at the desired depth within the
canalicular lumen while sheath 610 is retracted proximally to
expose implant 620.
[0091] Once implant 620 has been positioned in the canalicular
lumen at the desired depth in relation to the punctum, sheath 610
is retracted to expose implant 620 at the desired location in the
canalicular lumen. A plunger 630 can be used to retract sheath 610.
A shaft 640 mechanically couples sheath 610 to plunger 630. Thus,
retraction of plunger 630 in the proximal direction can retract
sheath 610 in the proximal direction to expose implant 620 at the
desired location in the canalicular lumen. Implant 620 can be any
of the implants as described herein. Often, implant 620 will
comprise a resilient member that expands to a large profile
configuration when sheath 610 is retracted. In many embodiments,
insertion tool 600 can include a dilator to dilate the punctum
prior to insertion of the implant, and the dilator can be
positioned on an end of the insertion tool that opposes the end
loaded with the implant, as described herein above.
[0092] FIGS. 5A to 5C schematically illustrate replacement of a
drug core 510 and a sheath body 520, according to an embodiment of
the present invention. An implant 700 comprises drug core 510,
sheath body 520 and a retention structure 530. Implant 500 can
include an occlusive element support by and movable with retention
structure 530. Often retention structure 530 can assume a first
small profile configuration prior to implantation and a second
large profile configuration while implanted. Retention structure
530 is shown in the large profile configuration and implanted in
the canalicular lumen. Sheath body 520 includes extension 525A and
extension 525B to attach the sheath body and drug core to retention
structure 530 so that the sheath body and drug core are retained by
retention structure 530. Drug core 510 and sheath body 520 can be
removed together by drawing drug core 510 proximally as shown by
arrow 530. Retention structure 530 can remain implanted in the
canalicular tissue after drug core 510 and sheath body 520 have
been removed as shown in FIG. 5B. A replacement core 560 and
replacement sheath body 570 can be inserted together as shown in
FIG. 5C. Such replacement can be desirable after drug core 510 has
released effective amounts of therapeutic agent such that the
supply of therapeutic agent in the drug core has diminished and the
rate of therapeutic agent released is near the minimum effective
level. Replacement sheath body 570 includes extension 575A and
extension 575B. Replacement drug core 560 and replacement sheath
body 570 can be advanced distally as shown by arrow 590 to insert
replacement drug core 560 and replacement sheath body 570 into
retention structure 530. Retention structure 530 remains at
substantially the same location while replacement drug core 560 and
replacement sheath body 570 are inserted into resilient member
530.
[0093] FIGS. 6A to 6C show deployment of a sustained release
implant, according to an embodiment of the present invention. As
shown in FIG. 6A, a deployment instrument 610 is inserted into a
canaliculus 600 through a punctum 600A. A sustained release implant
620 is loaded into a tip of deployment instrument 610, and a sheath
612 covers sustained release implant 620. Retention structure 630
assumes a small profile configuration while sheath 612 is
positioned over retention structure 630. As shown in FIG. 6B, outer
sheath 612 of deployment instrument 610 is withdrawn to expose a
retention structure 630 of sustained release implant 620. The
exposed portion of retention element 630 assumes a large profile
configuration. As shown in FIG. 6C, deployment instrument 610 has
been removed and sustained release implant 620 is implanted in
canaliculus 600. A drug core 640 is attached retention structure
630 and retained in the canaliculus. An outer body sheath 650
covers at least a portion of drug core 640 and drug core 640
releases a therapeutic agent into a liquid tear or tear film 660
near punctum 600A of canaliculus 600.
[0094] Sheath Body
[0095] The sheath body comprises appropriate shapes and materials
to control migration of the therapeutic agent from the drug core.
The sheath body houses the core and can fit snugly against the
core. The sheath body is made from a material that is substantially
impermeable to the therapeutic agent so that the rate of migration
of the therapeutic agent may be largely controlled by the exposed
surface area of the drug core that is not covered by the sheath
body. In many embodiments, migration of the therapeutic agent
through the sheath body can be about one tenth of the migration of
the therapeutic agent through the exposed surface of the drug core,
or less, often being one hundredth or less. In other words, the
migration of the therapeutic agent through the sheath body is at
least about an order of magnitude less that the migration of the
therapeutic agent through the exposed surface of the drug core.
Suitable sheath body materials include polyimide, polyethylene
terephthalate" (hereinafter "PET"). The sheath body has a
thickness, as defined from the sheath surface adjacent the core to
the opposing sheath surface away from the core, from about
0.00025'' to about 0.0015''. The total diameter of the sheath that
extends across the core ranges from about 0.2 mm to about 1.2 mm.
The core may be formed by dip coating the core in the sheath
material. Alternatively or in combination, the sheath body can
comprise a tube and the core introduced into the sheath, for
example as a liquid or solid that can be slid, injected and/or
extruded into the sheath body tube. The sheath body can also be dip
coated around the core, for example dip coated around a pre-formed
core.
[0096] The sheath body can be provided with additional features to
facilitate clinical use of the implant. For example, the sheath may
receive a drug core that is exchangeable while the retention
structure and sheath body remain implanted in the patient. The
sheath body is often rigidly attached to the retention structure as
described above, and the core is exchangeable while the retention
structure retains the sheath body. In specific embodiments, the
sheath body can be provided with external protrusions that apply
force to the sheath body when squeezed and eject the core from the
sheath body. Another drug core can then be positioned in the sheath
body. In many embodiments, the sheath body and/or retention
structure may have a distinguishing feature, for example a
distinguishing color, to show placement such that the placement of
the sheath body and/or retention structure in the canaliculus or
other body tissue structure can be readily detected by the patient.
The retention element and/or sheath body may comprise at least one
mark to indicate the depth of placement in the canaliculus such
that the retention element and/or sheath body can be positioned to
a desired depth in the canaliculus based on the at least one
mark.
[0097] Retention Structure
[0098] The retention structure comprises an appropriate material
that is sized and shaped so that the implant can be easily
positioned in the desired tissue location, for example the
canaliculus. The retention structure is mechanically deployable and
typically expands to a desired cross sectional shape, for example
with the retention structure comprising a super elastic shape
memory alloy such as Nitinol.TM.. Other materials in addition to
Nitinol.TM. can be used, for example resilient metals or polymers,
plastically deformable metals or polymers, shape memory polymers,
and the like, to provide the desired expansion. In some embodiments
polymers and coated fibers available from Biogeneral, Inc. of San
Diego, Calif. may be used. Many metals such as stainless steels and
non-shape memory alloys can be used and provide the desired
expansion. This expansion capability permits the implant to fit in
hollow tissue structures of varying sizes, for example canaliculae
ranging from 0.3 mm to 1.2 mm (i.e. one size fits all). Although a
single retention structure can be made to fit canaliculae from 0.3
to 1.2 mm across, a plurality of alternatively selectable retention
structures can be used to fit this range if desired, for example a
first retention structure for canaliculae from 0.3 to about 0.9 mm
and a second retention structure for canaliculae from about 0.9 to
1.2 mm. The retention structure has a length appropriate to the
anatomical structure to which the retention structure attaches, for
example a length of about 3 mm for a retention structure positioned
near the punctum of the canaliculus. For different anatomical
structures, the length can be appropriate to provide adequate
retention force, e.g. 1 mm to 15 mm lengths as appropriate.
[0099] Although the sheath body and drug core are attached to one
end of the retention structure as described above, in many
embodiments the other end of retention structure is not attached to
drug core and sheath body so that the retention structure can slide
over the sheath body and drug core while the retention structure
expands. This sliding capability on one end is desirable as the
retention structure may shrink in length as the retention structure
expands in width to assume the desired cross sectional width.
However, it should be noted that many embodiments may employ a
sheath body that does not slide in relative to the core.
[0100] In many embodiments, the retention structure can be
retrieved from tissue. A protrusion, for example a hook, a loop, or
a ring, can extend from the retention structure to facilitate
removal of the retention structure.
[0101] Occlusive Element
[0102] The occlusive element comprises an appropriate material that
is sized and shaped so that the implant can at least partially
inhibit, even block, the flow of fluid through the hollow tissue
structure, for example lacrimal fluid through the canaliculus. The
occlusive material shown is a thin walled membrane of a
biocompatible material, for example silicone, that can expand and
contract with the retention structure. The occlusive element is
formed as a separate thin tube of material that is slid over the
end of the retention structure and anchored to one end of the
retention structure as described above. Alternatively, the
occlusive element can be formed by dip coating the retention
structure in a biocompatible polymer, for example silicone polymer.
The thickness of the occlusive element can be in a range from about
0.01 mm to about 0.15 mm, and often from about 0.05 mm to 0.1
mm.
[0103] Therapeutic Agents
[0104] A "therapeutic agent" can comprise a drug may be any of the
following or their equivalents, derivatives or analogs, including,
anti-glaucoma medications, (e.g. adrenergic agonists, adrenergic
antagonists (beta blockers), carbonic anhydrase inhibitors (CATs,
systemic and topical), parasympathomimetics, prostaglandins and
hypotensive lipids, and combinations thereof), antimicrobial agent
(e.g., antibiotic, antiviral, antiparacytic, antifungal, etc.), a
corticosteroid or other anti-inflammatory (e.g., an NSAID), a
decongestant (e.g., vasoconstrictor), an agent that prevents of
modifies an allergic response (e.g., an antihistamine, cytokine
inhibitor, leucotriene inhibitor, IgE inhibitor, immunomodulator),
a mast cell stabilizer, cycloplegic or the like. Examples of
conditions that may be treated with the therapeutic agent(s)
include but are not limited to glaucoma, pre and post surgical
treatments, dry eye and allergies. In some embodiments, the
therapeutic agent may be a lubricant or a surfactant, for example a
lubricant to treat dry eye.
[0105] Exemplary therapeutic agents include, but are not limited
to, thrombin inhibitors; antithrombogenic agents; thrombolytic
agents; fibrinolytic agents; vasospasm inhibitors; vasodilators;
antihypertensive agents; antimicrobial agents, such as antibiotics
(such as tetracycline, chlortetracycline, bacitracin, neomycin,
polymyxin, gramicidin, cephalexin, oxytetracycline,
chloramphenicol, rifampicin, ciprofloxacin, tobramycin, gentamycin,
erythromycin, penicillin, sulfonamides, sulfadiazine,
sulfacetamide, sulfamethizole, sulfisoxazole, nitrofurazone, sodium
propionate), antifungals (such as amphotericin B and miconazole),
and antivirals (such as idoxuridine trifluorothymidine, acyclovir,
gancyclovir, interferon); inhibitors of surface glycoprotein
receptors; antiplatelet agents; antimitotics; microtubule
inhibitors; anti-secretory agents; active inhibitors; remodeling
inhibitors; antisense nucleotides; anti-metabolites;
antiproliferatives (including antiangiogenesis agents); anticancer
chemotherapeutic agents; anti-inflaTnmatories (such as
hydrocortisone, hydrocortisone acetate, dexamethasone 21-phosphate,
fluocinolone, medrysone, methylprednisolone, prednisolone
21-phosphate, prednisolone acetate, fluoromethalone, betamethasone,
triamcinolone, triamcinolone acetonide); non steroidal
anti-inflammatories (NSAIDs) (such as salicylate, indomethacin,
ibuprofen, diclofenac, flurbiprofen, piroxicam indomethacin,
ibuprofen, naxopren, piroxicam and nabumetone). Such anti
inflammatory steroids contemplated for use in the methodology of
the present invention, include triamcinolone acetonide (generic
name) and corticosteroids that include, for example, triamcinolone,
dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone,
and derivatives thereof); antiallergenics (such as sodium
chromoglycate, antazoline, methapyriline, chlorpheniramine,
cetrizine, pyrilamine, prophenpyridamine); anti proliferative
agents (such as 1,3-cis retinoic acid, 5-fluorouracil, taxol,
rapamycin, mitomycin C and cisplatin); decongestants (such as
phenylephrine, naphazoline, tetrahydrazoline); miotics and
anti-cholinesterase (such as pilocarpine, salicylate, carbachol,
acetylcholine chloride, physostigmine, eserine, diisopropyl
fluorophosphate, phospholine iodine, demecarium bromide);
antineoplastics (such as carmustine, cisplatin, fluorouracil3;
immunological drugs (such as vaccines and immune stimulants);
hormonal agents (such as estrogens, -estradiol, progestational,
progesterone, insulin, calcitonin, parathyroid hormone, peptide and
vasopressin hypothalamus releasing factor); immunosuppressive
agents, growth hormone antagonists, growth factors (such as
epidermal growth factor, fibroblast growth factor, platelet derived
growth factor, transforming growth factor beta, somatotrapin,
fibronectin); inhibitors of angiogenesis (such as angiostatin,
anecortave acetate, thrombospondin, anti-VEGF antibody); dopamine
agonists; radiotherapeutic agents; peptides; proteins; enzymes;
extracellular matrix; components; ACE inhibitors; free radical
scavengers; chelators; antioxidants; anti polymerases; photodynamic
therapy agents; gene therapy agents; and other therapeutic agents
such as prostaglandins, antiprostaglandins, prostaglandin
precursors, including antiglaucoma drugs including beta-blockers
such as Timolol, betaxolol, levobunolol, atenolol, and
prostaglandin analogues such as Bimatoprost, travoprost,
Latanoprost etc; carbonic anhydrase inhibitors such as
acetazolamide, dorzolamide, brinzolamide, methazolamide,
dichlorphenamide, diamox; and neuroprotectants such as lubezole,
nimodipine and related compounds; and parasympathomimetrics such as
pilocarpine, carbachol, physostigmine and the like.
[0106] The amount of drug associated with the drug-delivery device
may vary depending on the particular agent, the desired therapeutic
benefit and the time during which the device is intended to deliver
the therapy. Since the devices of the present invention present a
variety of shapes, sizes and delivery mechanisms, the amount of
drug associated with the device will depend on the particular
disease or condition to be treated, and the dosage and duration
that is desired to achieve the therapeutic effect. Generally, the
amount of drug is at least the amount of drug that upon release
from the device, is effective to achieve the desired physiological
or pharmacological local or systemic effects.
[0107] Embodiments of the drug delivery devices of the present
invention can be adapted to provide delivery of drug at a daily
rate that is substantially below the therapeutically effective drop
form of treatment so as to provide a large therapeutic range with a
wide safety margin. For example, many embodiments treat the eye
with therapeutic levels for extended periods that are no more than
5 or 10 per cent of the daily drop dosage. Consequently, during an
initial bolus or washout period of about one to three days, the
implant can elute the therapeutic agent at a rate that is
substantially higher than the sustained release levels and well
below the daily drop form dosage. For example, with an average
sustained release level of 100 ng per day, and an initial release
rate of 1000 to 1500 ng per day, the amount of drug initially
released is less than the 2500 ng of drug that may be present in a
drop of drug delivered to the eye. This used use of sustained
release levels substantially below the amount of drug in a drop
and/or drops administered daily allows the device to release a
therapeutically beneficial amount of drug to achieve the desired
therapeutic benefit with a wide safety margin, while avoiding an
inadequate or excessive amount of drug at the intended site or
region.
[0108] An extended period of time may mean a relatively short
period of time, for example minutes or hours (such as with the use
of an anesthetic), through days or weeks (such as the use of
pre-surgical or post-surgical antibiotics, steroids, or NSAIDs and
the like), or longer (such as in the case of glaucoma treatments),
for example months or years (on a recurring basis of use of the
device).
[0109] For example, a drug such as Timolol maleate, a beta1 and
beta2 (non-selective) adrenergic receptor blocking agent can be
used in the device for a release over an extended period of time
such as 3 months. Three months is a relatively typical elapsed time
between physician visits for a glaucoma patient undergoing topical
drop therapy with a glaucoma drug, although the device could
provide treatment for longer or shorter durations. In the three
month example, a 0.25% concentration of Timolol translates to from
2.5 to 5 mg/1000 .mu.L, typically being 2.5 mg/1000 .mu.L. A drop
of Timolol for topical application is usually in the range of 40-60
.mu.L, typically being 50 .mu.L. Thus, there may be 0.08-0.15 mg,
typically being 0.125 mg of Timolol in a drop. There may be
approximately 8% (optionally 6-10%) of the drop left in the eye
after 5 minutes, so about 10 .mu.g of the drug is available at that
time. Timolol may have a bioavailability of 30-50%, which means
that from 1.5 to 7.5 .mu.g, for example 4 .mu.g of the drug is
available to the eye. Timolol is generally applied twice a day, so
8 (or 3-15).mu.g is available to the eye each day. Therefore, a
delivery device might contain from 270 to 1350 .mu.g, for example
720 .mu.g, of the drug for a 90 day, or 3 month, extended release.
The drug would be contained within the device and eluted based on
the polymer or drug/hydrogel concentration. The drug can be
similarly contained on the device and eluted for olopatadine
hydrochloride (Patanol.RTM.) and other drugs in a manner similar to
Timolol.
[0110] Commercially available solutions of Timolol maleate are
available in 0.25% and 0.5% preparations, and the initial dosage
can be 1 drop twice per day of 0.25% solution. A 0.25%
concentration of Timolol is equivalent to 2.5 mg per 1000 .mu.l. A
sustained release quantity of Timolol released each day from the
drug core can be from about 3 to 15 .mu.g each day. Although the
sustained release quantity delivered each day from the device may
vary, a sustained release delivery of about 8 .mu.g per day
corresponds to about 3.2% of the 0.250 mg of Timolol applied with
two drops of a 0.25% solution.
[0111] For example, in the case of Latanoprost (Xalatan), a
prostaglandin F2.alpha. analogue, this glaucoma medication has
concentrations that are about 1/10.sup.th that of Timolol.
Therefore, the amount of drug on the implantable device, depending
on the bioavailability, would be significantly less--approximately
20-135 .mu.g and typically 50-100 .mu.g--for Latanoprost and other
prostaglandin analogues. This also translates to a device that can
either be smaller than one required for a beta blocker delivery or
can house more drug for a longer release period.
[0112] A drop of Xalatan contains about 2.5 .mu.g of Latanoprost,
assuming a 50 .mu.L drop volume. Therefore, assuming that about 8%
of 2.5 .mu.g is present 5 minutes after instillation, only about
200 ng of drug remains on the eye. Based on the Latanoprost
clinical trials, this amount is effective in lowering IOP for at
least 24 hours. Pfizer/Pharmacia conducted several dose-response
studies in support of the NDA for Xalatan. The doses ranged from
12.5 .mu.g/mL to 115 .mu.g/mL of Latanoprost. The current dose of
Latanoprost, 50 .mu.g/mL, given once per day, was shown to be
optimal. However, even the lowest doses of 12.5 .mu.g/mL QD or 15
.mu.g/mL BID consistently gave about 60-75% of the IOP reduction of
the 50 .mu.g/mL QD dose. Based on the assumptions above, a 12.5
.mu.g/mL concentration provides 0.625 .mu.g of Latanoprost in a 50
.mu.L drop, which results in only about 50 ng (8%) of drug
remaining in the eye after 5 minutes.
[0113] In many embodiments, the concentrations of Latanoprost are
about 1/100.sup.th, or 1 per cent, that of Timolol, and in specific
embodiments the concentrations of Latanoprost may be about
1/50.sup.th, or 2 percent, that of Timolol. For example,
commercially available solution preparations of Latanoprost are
available at concentrations 0.005%, often delivered with one drop
per day. In many embodiments, the therapeutically effective
concentration of drug released from the device per day can be about
1/100th of Timolol, about 30 to 150 ng per day, for example about
80 ng, assuming tear washout and bioavailability similar to
Timolol. For example, the amount of drug on the implantable device,
can be significantly less--approximately 1% to 2% of Timolol, for
example 2.7 to 13.5 .mu.g, and can also be about 3 to 20 .mu.g, for
Latanoprost and other prostaglandin analogues. Although the
sustained release amount of Latanoprost released each day can vary,
a sustained release of 80 ng per day corresponds to about 3.2% of
the 2.5 .mu.g of Latanoprost applied with a single drop of a 0.005%
solution
[0114] For example, in the case of Bimatoprost (Lumigan), a
synthetic prostamide prostaglandin analogue, this glaucoma
medication may have concentrations that are 1/20.sup.th or less
than that of Timolol. Therefore, the amount of drug loaded on the
extended release device for a 3 to 6 month extended release,
depending on the bioavailability, can be significantly less,
approximately 5-30 .mu.g and typically 10-20 .mu.g--for Bimatoprost
and analogues and derivatives thereof. In many embodiments, the
implant can house more drug for a longer sustained release period,
for example 20-40 .mu.g for a sustained release period of 6 to 12
months with Bimatoprost and its derivatives. This decrease in drug
concentration can also translate to a device that can be smaller
than one required for a beta blocker delivery.
[0115] Commercially available solution concentrations of
Bimatoprost are 0.03% by weight, often delivered once per day.
Although the sustained release amount of Bimatoprost released each
day can vary, a sustained release of 300 ng per day corresponds to
about 2% of the 15 .mu.g of Bimatoprost applied with a single drop
of a 0.03% solution. Work in relation with the present invention
suggests that even lower sustained release doses of Bimatoprost can
provide at least some reduction in intraocular pressure, for
example 20 to 200 ng of Bimatoprost and daily sustained release
dosages of 0.2 to 2% of the daily drop dosage.
[0116] For example, in the case of Travoprost (Travatan), a
prostaglandin F2.alpha. analogue, this glaucoma medication may have
concentrations that are 2% or less than that of Timolol. For
example, commercially available solution concentrations are 0.004%,
often delivered once per day. In many embodiments, the
therapeutically effective concentration of drug released from the
device per day can be about 65 ng, assuming tear washout and
bioavailability similar to Timolol. Therefore, the amount of drug
on the implantable device, depending on the bioavailability, would
be significantly less. This also translates to a device that can
either be smaller than one required for a beta blocker delivery or
can house more drug for a longer release period. For example, the
amount of drug on the implantable device, can be significantly
less--approximately 1/100 of Timolol, for example 2.7 to 13.5
.mu.g, and typically about 3 to 20 .mu.g, for Travoprost,
Latanoprost and other prostaglandin F2.alpha. analogues. Although
the sustained release amount of Latanoprost released each day can
vary, a sustained release of 65 ng per day corresponds to about
3.2% of the 2.0 .mu.g of Travoprost applied with a single drop of a
0.004% solution.
[0117] In some embodiments, the therapeutic agent may comprise a
cortico steriod, for example fluocinolone acetonide, to treat a
target ocular tissue. In specific embodiments, fluocinolone
acetonide can be released from the canaliculus and delivered to the
retina as a treatment for diabetic macular edema (DME).
[0118] It is also within the scope of this invention to modify or
adapt the devices to deliver a high release rate, a low release
rate, a bolus release, a burst release, or combinations thereof. A
bolus of the drug may be released by the formation of an erodable
polymer cap that is immediately dissolved in the tear or tear film.
As the polymer cap comes in contact with the tear or tear film, the
solubility properties of the polymer enable the cap to erode and
the drug is released all at once. A burst release of a drug can be
performed using a polymer that also erodes in the tear or tear film
based on the polymer solubility. In this example, the drug and
polymer may be stratified along the length of the device so that as
the outer polymer layer dissolves, the drug is immediately
released. A high or low release rate of the drug could be
accomplished by changing the solubility of the erodable polymer
layer so that the drug layer released quickly or slowly. Other
methods to release the drug could be achieved through porous
membranes, soluble gels (such as those in typical ophthalmic
solutions), microparticle encapsulations of the drug, or
nanoparticle encapsulation, depending on the size of the drug
molecule.
[0119] Drug Core
[0120] The drug core comprises the therapeutic agent and materials
to provide sustained release of the therapeutic agent. The
therapeutic agent migrates from the drug core to the target tissue,
for example ciliary muscles of the eye. The therapeutic agent may
optionally be only slightly soluble in the matrix so that a small
amount of therapeutic agent is dissolved in the matrix and
available for release from the surface of drug core 110. As the
therapeutic agent diffuses from the exposed surface of the core to
the tear or tear film, the rate of migration from the core to the
tear or tear film can be related to the concentration of
therapeutic agent dissolved in the matrix. In addition or in
combination, the rate of migration of therapeutic agent from the
core to the tear or tear film can be related to properties of the
matrix in which the therapeutic agent dissolves. In specific
embodiments, the rate of migration from the drug core to the tear
or tear film can be based on a silicone formulation. In some
embodiments, the concentration of therapeutic agent dissolved in
the drug core may be controlled to provide the desired rate of
release of the therapeutic agent. The therapeutic agent included in
the core can include liquid, solid, solid gel, solid crystalline,
solid amorphous, solid particulate, and/or dissolved forms of the
therapeutic agent. In a preferred embodiment, the drug core
comprises a silicone matrix containing the therapeutic agent. The
therapeutic agent may comprise liquid or solid inclusions, for
example liquid Latanoprost droplets or solid Bimatoprost particles,
respectively, dispersed in the silicone matrix.
[0121] The drug core can comprise one or more biocompatible
materials capable of providing a sustained release of the
therapeutic agent. Although the drug core is described above with
respect to an embodiment comprising a matrix with a substantially
non-biodegradable silicone matrix with inclusions of the drug
located therein that dissolve, the drug core can include structures
that provide sustained release of the therapeutic agent, for
example a biodegradable matrix, a porous drug core, liquid drug
cores and solid drug cores. A matrix that contains the therapeutic
agent can be formed from either biodegradable or non-biodegradable
polymers. A non-biodegradable drug core can include silicone,
acrylates, polyethylenes, polyurethane, polyurethane, hydrogel,
polyester (e.g., DACRON.RTM. from E. I. Du Pont de Nemours and
Company, Wilmington, Del.), polypropylene, polytetrafluoroethylene
(PTFE), expanded PTFE (ePTFE), polyether ether ketone (PEEK),
nylon, extruded collagen, polymer foam, silicone rubber,
polyethylene terephthalate, ultra high molecular weight
polyethylene, polycarbonate urethane, polyurethane, polyimides,
stainless steel, nickel-titanium alloy (e.g., Nitinol), titanium,
stainless steel, cobalt-chrome alloy (e.g., ELGILOY.RTM. from Elgin
Specialty Metals, Elgin, Ill.; CONICHROME.RTM. from Carpenter
Metals Corp., Wyomissing, Pa.). A biodegradable drug core can
comprise one or more biodegradable polymers, such as protein,
hydrogel, polyglycolic acid (PGA), polylactic acid (PLA),
poly(L-lactic acid) (PLLA), poly(L-glycolic acid) (PLGA),
polyglycolide, poly-L-lactide, poly-D-lactide, poly(amino acids),
polydioxanone, polycaprolactone, polygluconate, polylactic
acid-polyethylene oxide copolymers, modified cellulose, collagen,
polyorthoesters, polyhydroxybutyrate, polyanhydride,
polyphosphoester, poly(alpha-hydroxy acid) and combinations
thereof. In some embodiments the drug core can comprise at least
one of hydrogel polymer.
[0122] Release of Therapeutic Agent at Effective Levels
[0123] The rate of release of the therapeutic agent can be related
to the concentration of therapeutic agent dissolved in the drug
core. In many embodiments, the drug core comprises non-therapeutic
agents that are selected to provide a desired solubility of the
therapeutic agent in the drug core. The non-therapeutic agent of
the drug core can comprise polymers as described herein and
additives. A polymer of the core can be selected to provide the
desired solubility of the therapeutic agent in the matrix. For
example, the core can comprise hydrogel that may promote solubility
of hydrophilic treatment agent. In some embodiments, functional
groups can be added to the polymer to provide the desired
solubility of the therapeutic agent in the matrix. For example,
functional groups can be attached to silicone polymer.
[0124] In some embodiments, additives may be used to control the
release kinetics of therapeutic agent. For example, the additives
may be used to control the concentration of therapeutic agent by
increasing or decreasing solubility of the therapeutic agent in the
drug core so as to control the release kinetics of the therapeutic
agent. The solubility may be controlled by providing appropriate
molecules and/or substances that increase and/or decrease the
solubility of the dissolved from of the therapeutic agent to the
matrix. The solubility of the dissolved from the therapeutic agent
may be related to the hydrophobic and/or hydrophilic properties of
the matrix and therapeutic agent. For example, surfactants,
tinuvin, salts and water can be added to the matrix and may
increase the solubility of hydrophilic therapeutic agent in the
matrix. In addition, oils and hydrophobic molecules and can be
added to the matrix and may increase the solubility of hydrophobic
treatment agent in the matrix.
[0125] Instead of or in addition to controlling the rate of
migration based on the concentration of therapeutic agent dissolved
in the matrix, the surface area of the drug core can also be
controlled to attain the desired rate of drug migration from the
core to the target site. For example, a larger exposed surface area
of the core will increase the rate of migration of the treatment
agent from the drug core to the target site, and a smaller exposed
surface area of the drug core will decrease the rate of migration
of the therapeutic agent from the drug core to the target site. The
exposed surface area of the drug core can be increased in any
number of ways, for example by any of castellation of the exposed
surface, a porous surface having exposed channels connected with
the tear or tear film, indentation of the exposed surface,
protrusion of the exposed surface. The exposed surface can be made
porous by the addition of salts that dissolve and leave a porous
cavity once the salt dissolves. Hydrogels may also be used, and can
swell in size to provide a larger exposed surface area. Such
hydrogels can also be made porous to further increase the rate of
migration of the therapeutic agent.
[0126] Further, an implant may be used that includes the ability to
release two or more drugs in combination, such as the structure
disclosed in U.S. Pat. No. 4,281,654 (Shell). For example, in the
case of glaucoma treatment, it may be desirable to treat a patient
with multiple prostaglandins or a prostaglandin and a cholinergic
agent or an adrenergic antagonist (beta blocker), such as
Alphagan.RTM., or a prostaglandin and a carbonic anhydrase
inhibitor.
[0127] In addition, drug impregnated meshes may be used such as
those disclosed in US Patent Publication No. 2002/0055701 or
layering of biostable polymers as described in US Patent
Publication No. 2005/0129731. Certain polymer processes may be used
to incorporate drug into the devices of the present invention such
as, so-called "self-delivering drugs" or PolymerDrugs (Polymerix
Corporation, Piscataway, N.J.) are designed to degrade only into
therapeutically useful compounds and physiologically inert linker
molecules, further detailed in US Patent Publication No.
2005/0048121 (East), hereby incorporated by reference in its
entirety. Such delivery polymers may be employed in the devices of
the present invention to provide a release rate that is equal to
the rate of polymer erosion and degradation and is constant
throughout the course of therapy. Such delivery polymers may be
used as device coatings or in the form of microspheres for a drug
depot injectable (such as a reservoir of the present invention). A
further polymer delivery technology may also be adapted to the
devices of the present invention such as that described in US
Patent Publication No. 2004/0170685 (Carpenter), and technologies
available from Medivas (San Diego, Calif.).
[0128] In specific embodiments, the drug core matrix comprises a
solid material, for example silicone, that encapsulates inclusions
of the drug. The drug comprises molecules which are very insoluble
in water and slightly soluble in the encapsulating drug core
matrix. The inclusions encapsulated by the drug core can be
micro-particles having dimensions from about 1 .mu.m to about 100
.mu.m across. The drug inclusions can comprise crystals, for
example Bimatoprost crystals, and/or droplets of oil, for example
with Latanoprost oil. The drug inclusions can dissolve into the
solid drug core matrix and substantially saturate the drug core
matrix with the drug, for example dissolution of Latanoprost oil
into the solid drug core matrix. The drug dissolved in the drug
core matrix is transported, often by diffusion, from the exposed
surface of the drug core into the tear film. As the drug core is
substantially saturated with the drug, in many embodiments the rate
limiting step of drug delivery is transport of the drug from the
surface of the drug core matrix exposed to the tear film. As the
drug core matrix is substantially saturated with the drug,
gradients in drug concentration within the matrix are minimal and
do not contribute significantly to the rate of drug delivery. As
surface area of the drug core exposed to the tear film is nearly
constant, the rate of drug transport from the drug core into the
tear film can be substantially constant. Work in relation with the
present invention suggests that the solubility of the therapeutic
agent in water and molecular weight of the drug can effect
transport of the drug from the solid matrix to the tear. In many
embodiments, the therapeutic agent is nearly insoluble in water and
has a solubility in water of about 0.03% to 0.002% by weight and a
molecular weight from about 400 grams/mol. to about 1200
grams/mol.
[0129] In many embodiments the therapeutic agent has a very low
solubility in water, for example from about 0.03% by weight to
about 0.002% by weight, a molecular weight from about 400 grams per
mole (g/mol.) to about 1200 g/mol, and is readily soluble in an
organic solvent. Cyclosporin A (CsA) is a solid with an aqueous
solubility of 27.67 .mu.g/mL at 25.degree. C., or about 0.0027% by
weight, and a molecular weight (M.W.) of 1202.6 g/mol. Latanoprost
(Xalatan) is a prostaglandin F2.alpha. analogue, a liquid oil at
room temperature, and has an aqueous solubility of 50 .mu.g/mL in
water at 25.degree. C., or about 0.005% by weight and a M.W. of
432.6 g/mol. Bimatoprost (Lumigan) is a synthetic prostamide
analogue, a solid at room temperature solubility in water of 300
.mu.g/mL in water at 25.degree. C., or 0.03% by weight, and has a
M.W. of 415.6 g/mol.
[0130] Work in relation with the present invention indicates that
naturally occurring surfactants in the tear film, for example
surfactant D and phospholipids, may effect transport of the drug
dissolved in the solid matrix from the core to the tear film. The
drug core can be adapted in response to the surfactant in the tear
film to provide sustained delivery of the drug into the tear film
at therapeutic levels. For example, empirical data can be generated
from a patient population, for example 10 patients whose tears are
collected and analyzed for surfactant content. Elution profiles in
the collected tears for a drug that is sparingly soluble in water,
for example cyclosporine, can also be measured and compared with
elution profiles in buffer and surfactant such that an in vitro
model of tear surfactant is developed. An in vitro solution with
surfactant based on this empirical data can be used to adjust the
drug core in response to the surfactant of the tear film.
[0131] The drug cores may also be modified to utilize carrier
vehicles such as nanoparticles or microparticles depending on the
size of the molecule to be delivered such as latent-reactive
nanofiber compositions for composites and nanotextured surfaces
(Innovative Surface Technologies, LLC, St. Paul, Minn.),
nanostructured porous silicon, known as BioSilicon.RTM., including
micron sized particles, membranes, woven fivers or micromachined
implant devices (pSividia, Limited, UK) and protein nanocage
systems that target selective cells to deliver a drug
(Chimeracore).
[0132] In many embodiments, the drug insert comprises of a
thin-walled polyimide tube sheath with a drug core comprising
Latanoprost dispersed in Nusil 6385 (MAF 970), a medical grade
solid silicone that serves as the matrix for drug delivery. The
distal end of the drug insert is sealed with a cured film of solid
Loctite 4305 medical grade adhesive. The drug insert may be placed
within the bore of the punctum plug, the Loctite 4305 adhesive does
not come into contact with either tissue or the tear film. The
inner diameter of the drug insert can be 0.32 mm; and the length
can be 0.95 mm. Three Latanoprost concentrations in the finished
drug product can be tested clinically: Drug cores can comprise 3.5,
7 or 14 .mu.g Latanoprost, with per cent by weight concentrations
of 5, 10 and 20% respectively. Assuming an overall elution rate of
approximately 100 ng/day, the drug core comprising 14 .mu.g of
Latanoprost is adapted to deliver drug for approximately at least
100 days, for example 120 days. The overall weight of the drug
core, including Latanoprost, can be .about.70 .mu.g. The weight of
the drug insert including the polyimide sleeve can be approximately
100 .mu.g.
[0133] In many embodiments, the drug core may elute with an initial
elevated level of therapeutic agent followed by substantially
constant elution of the therapeutic agent. In many instances, an
amount of therapeutic agent released daily from the core may be
below the therapeutic levels and still provide a benefit to the
patient. An elevated level of eluted therapeutic agent can result
in a residual amount of therapeutic agent and/or residual effect of
the therapeutic agent that is combined with a sub-therapeutic
amount of therapeutic agent to provide relief to the patient. In
embodiments where therapeutic level is about 80 ng per day, the
device may deliver about 100 ng per day for an initial delivery
period. The extra 20 ng delivered per day can have a beneficial
effect when therapeutic agent is released at levels below the
therapeutic level, for example at 60 ng per day. As the amount of
drug delivered can be precisely controlled, an initial elevated
dose may not result in complications and/or adverse events to the
patient.
Example 1
Latanoprost Drug Core Elution Data
[0134] Drug cores as described above have been fabricated with
different cross sectional sizes of 0.006 inches, 0.012 inches, and
0.025 inches, and drug concentrations of 5%, 10% and 20% in a
silicone matrix. Theses drug cores can be made with a Syringe Tube
and Cartridge Assembly, Mixing Latanoprost with Silicone, and
Injecting the mixture into a polyimide tube which is cut to desired
lengths and sealed. The length of the drug cores were approximately
0.80 to 0.95 mm, which for a diameter of 0.012 inches (0.32 mm)
corresponds to total Latanoprost content in the drug cores of
approximately 3.5 .mu.g, 7 .mu.g and 14 .mu.g for concentrations of
5%, 10% and 20%, respectively.
[0135] Syringe Tube and Cartridge Assembly. 1. Take polyimide
tubing of three different diameters 0.006 inches, 0.0125 inches and
0.025 inches. 2. Cut polyimide tubing of different diameters to -15
cm length. 3. Insert Polyimide tubes into a Syringe Adapter. 4.
Adhesive bond polyimide tube into luer adapter (Loctite, low
viscosity UV cure). 5. Trim end of assembly. 6. Clean the cartridge
assembly using distilled water and then with methanol and dry it in
oven at 60.degree. C.
[0136] Mix Latanoprost with Silicone. Prepare Latanoprost.
Latanoprost is provided as a 1% solution in methylacetate. Place
the appropriate amount of solution into a dish and using a nitrogen
stream, evaporate the solution until only the Latanoprost remains.
Place the dish with the Latanoprost oil under vacuum for 30
minutes. Combine Latanoprost with silicone. Prepare three different
concentrations of Latanoprost (5%, 10% and 20%) in silicon Nusil
6385 and inject it into tubing of different diameters (0.006 in,
0.012 in and 0.025 inches) to generate 3.times.3 matrixes. The
percent of Latanoprost to silicone is determined by the total
weight of the drug matrix. Calculation: Weight of
Latanoprost/(weight of Latanoprost+weight of
silicone).times.100=percent drug.
[0137] Inject tube. 1. Insert Cartridge and Polyimide tubes
assembly into 1 ml syringe. 2. Add one drop of catalyst, (MED-6385
Curing Agent) in the syringe. 3. Force excess catalyst out of the
polyimide tube with clean air. 4. Fill syringe with silicone drug
matrix. 5. Inject tube with drug matrix until the tube is filled or
the syringe plunger becomes too difficult to push. 6. Close off the
distal end of the polyimide tube and maintain pressure until the
silicone begins to solidify. 7. Allow to cure at room temperature
for 12 hours. 8. Place under vacuum for 30 minutes. 9. Place tube
in right size trim fixture (prepared in house to hold different
size tubing) and cut drug inserts to length (0.80-0.95 mm).
[0138] Testing. Elution study (in vitro). 1. Place 10 plugs of same
size and same concentration per centrifuge tube and add 1.5 ml of
7.4 pH buffer solution to it. 2. Change the solvent with fresh 7.4
pH buffer after appropriate time. 3. Take HPLC of the elutant at
210 nm with PDA detector 2996 using Sunfire C18, 3 mm.times.10 mm
column (Waters Corporation, Milford, Mass.). Acetonitrile and water
mixture is used for gradient elution. Calibration was done in house
before and after each analysis, using in-house standards with
precisely weighed concentration of Latanoprost. 4. Calculate the
amount of drug release per day per device for different size
tubings having different concentrations of Latanoprost. 5. Plot
elution rate vs area and concentration for day 1 and day 14.
[0139] FIGS. 7A and 7B show elution data of Latanoprost at day 1
and day 14, respectively, for the three core diameters of 0.006,
0.012 and 0.025 inches and three Latanoprost concentrations of
approximately 5%, 11% and 18%. Elution rate of the Latanoprost in
nanograms (ng) per day is plotted versus percent concentration.
These data show that the rate of elution is mildly dependent on the
concentration and strongly dependent on the exposed surface area at
both time periods. At day 1, the 0.006 inch, 0.012 inch and 0.025
inch diameter cores released about 200 ng, 400 ng and 1200 ng of
Latanoprost, respectively, showing that the quantity of Latanoprost
released increases with an increased size of the exposed surface
area of the drug core. For each tube diameter, the quantity of
Latanoprost released is compared to the concentration of drug in
the drug core with a least square regression line. For the 0.006,
0.012 and 0.025 inch drug cores the slope of the regression lines
are 11.8, 7.4 and 23.4, respectively. These values indicate that a
doubling of concentration of the Latanoprost drug in the core does
not lead to a doubling of the elution rate of the Latanoprost from
the core, consistent with droplets of Latanoprost suspended in a
drug core matrix and substantial saturation of the drug core matrix
with Latanoprost dissolved therein, as described above.
[0140] At day 14, the 0.006 inch, 0.012 inch (0.32 mm) and 0.025
inch diameter cores released about 25 ng, 100 ng and 300 ng of
Latanoprost, respectively, showing that the quantity of Latanoprost
released increases with an increased size of the exposed surface
area of the drug core at extended periods of time, and that the
quantity of Latanoprost released is mildly dependent on the
concentration of therapeutic agent in the core. For each tube
diameter, the quantity of Latanoprost released is compared to the
concentration of drug in the drug core with a least square
regression line. For the 0.006, 0.012 and 0.025 inch drug cores the
slope of the regression lines are 3.0, 4.3 and 2.2, respectively.
For the 0.012 and 0.025 inch cores, these values indicate that a
doubling of concentration of the Latanoprost drug in the core does
not lead to a doubling of the elution rate of the Latanoprost from
the core, consistent with droplets of Latanoprost suspended in a
drug core matrix and substantial saturation of the drug core matrix
with Latanoprost dissolved therein, as described above. However,
for the 0.006 inch diameter core, there is an approximately first
order relationship between the quantity of initially in the core
and the amount of drug released at day 14, which can may be caused
by depletion of Latanoprost drug droplets in the core.
[0141] FIGS. 7D and 7E show dependence of the rate of elution on
exposed surface area of the drug core for the three core diameters
and the three concentrations as in FIGS. 7A and 7B Latanoprost at
day 1 and day 14, respectively, according to embodiments of the
present invention. Elution rate of the Latanoprost in nanograms
(ng) per day is plotted versus the exposed surface area of the drug
core in mm.sup.2 as determined by the diameter of the drug core.
These data show that the rate of elution is mildly dependent on the
concentration of drug in the core and strongly dependent on the
exposed surface area at both one day and a 14 days. The exposed
surface areas of the 0.006 inch, 0.012 inch and 0.025 inch diameter
cores are approximately 0.02, 0.07, and 0.32 mm.sup.2,
respectively. At day 1, the 0.02, 0.07, and 0.32 mm.sup.2, cores
released about 200 ng, 400 ng and 1200 ng of Latanoprost,
respectively, showing that the quantity of Latanoprost released
increases with an increased size of the exposed surface area of the
drug core. For each concentration of therapeutic agent in the drug
core, the quantity of Latanoprost released is compared to the
exposed surface area of the drug core with a least square
regression line. For the 5.1%, 11.2%, and 17.9% drug cores the
slope of the regression lines are 2837.8, 3286.1 and 3411.6,
respectively, with R.sup.2 coefficients of 0.9925, 0.9701 and 1,
respectively. At day 14, the 0.02, 0.07, and 0.32 mm.sup.2, cores
released about 25 ng, 100 ng and 300 ng of Latanoprost,
respectively showing that the quantity of Latanoprost released
increases with an increased size of the exposed surface area of the
drug core. For the 5.1%, 11.2%, and 17.9% drug cores the slope of
the regression lines are 812.19, 1060.1 and 764.35, respectively,
with R.sup.2 coefficients of 0.9904, 0.9924 and 0.9663,
respectively. These values indicate the elution rate of the
Latanoprost from the core increases linearly with the surface area
of the drug core, consistent with a drug sheath that can control
the exposed surface area, as described above. The weak dependence
of Latanoprost elution on concentration in the drug core is
consistent with droplets of Latanoprost suspended in a drug core
matrix and substantial saturation of the drug core matrix with
Latanoprost dissolved therein, as described above.
[0142] FIG. 7C shows elution data for Latanoprost from 0.32 mm
diameter, 0.95 mm long drug cores with concentrations of 5, 10 and
20% and drug weights of 3.5, 7 and 14 .mu.g, respectively,
according to embodiments of the present invention. The drug cores
were manufactured as described above. The elution rate is plotted
in ng per day from 0 to 40 days. The 14 .mu.g core shows rates of
approximately 100 ng per day from about 10 to 40 days. The 7 .mu.g
core shows comparable rates from 10 to 20 days. These data are
consistent with droplets of Latanoprost suspended in a drug core
matrix and substantial saturation of the drug core matrix with
Latanoprost dissolved therein, as described above.
[0143] Table 2 shows the expected parameters for each drug
concentration. As shown in FIG. 1C, in vitro results in a buffered
saline elution system show that the plug initially elutes
approximately 500 ng of Latanoprost per day, dropping off rapidly
within 7-14 days to approximately 100 ng/day, depending on the
initial concentration of drug.
TABLE-US-00001 TABLE 2 Drug Elution Properties Total Latanoprost
content 14 .mu.g 7 .mu.g 3.5 .mu.g In vitro elution rate See FIG.
1C See FIG. 1C See FIG. 1C Duration ~100 days ~45 days ~25 days
[0144] In many embodiments, the duration of the drug core can be
determined based on the calculated time when .about.10% of the
original amount of drug remains in drug insert, for example where
the elution rate levels out and remains substantially constant at
approximately 100 ng/day.
Example 2
Cyclosporin Drug Core Elution Data
[0145] Drug cores as described in Example 1 were made with
cyclosporin having a concentration of 21.2%. FIG. 8A shows elution
profiles of cyclosporin from drug cores into a buffer solution
without surfactant and into a buffer solution with surfactant,
according to embodiments of the present invention. The buffer
solution was made as described above. The solution with surfactant
includes 95% buffer and 5% surfactant, UP-1005 Ultra Pure Fluid
from Dow Corning, Midland Mich. Work in relation with embodiments
of the present invention indicates that in at least some instances,
surfactants may be used in in vitro to model in situ elution from
the eye as the eye can include natural surfactants, for example
Surfactant Protein D, in the tear film. The elution profile of
cyclosporin into surfactant is approximately 50 to 100 ng per day
from 30 to 60 days. Empirical data from tears of a patient
population, for example 10 patients, can be measured and used to
refine the in vitro model with appropriate amounts of surfactant.
The drug core matrix may be modified in response to the human tear
surfactant as determined with the modified in vitro model. The drug
core can be modified in many ways in response to the human tear
film surfactant, for example with an increased exposed surface area
and/or additives to increase an amount of cyclosporine drug
dissolved in the core, as described above, to increase elution from
the core to therapeutic levels, if appropriate.
Example 3
Bimatoprost Bulk Elution Data
[0146] Bulk samples of 1% Bimatoprost having a known diameter of
0.076 cm (0.76 mm) were prepared. The height of each sample was
determined from the weight and known diameter of the sample.
TABLE-US-00002 TABLE 2 Bulk Sample Size calculated Exposed Surface
sample wt (mg) diameter (cm) height (cm) Area (cm{circumflex over (
)}2) 14-2-10 1.9 0.076 0.42 0.109 14-2-11 1.5 0.076 0.33 0.088
14-2-12 1.9 0.076 0.42 0.109
[0147] The calculated heights ranged from 0.33 cm to 0.42 cm. The
exposed surface area on each end of each bulk sample was
approximately 0.045 cm.sup.2, providing volumes of 0.019 cm.sup.3
and 0.015 cm.sup.3 for the 0.42 and 0.33 cm samples, respectively.
The exposed an exposed surface area of samples calculated from the
height and diameter without a drug sheath was approximately 0.1
cm.sup.2. Three formulations were evaluated: 1) silicone 4011, 1%
Bimatoprost, 0% surfactant; 2) silicone 4011, 1% Bimatoprost,
approximately 11% surfactant; and 3) silicone 4011, 1% Bimatoprost,
approximately 33% surfactant. The elution data measured for the
bulk samples with formulation 1, 2 and 3 were normalized to ng per
device per day (ng/device/day) assuming a surface area of the bulk
device is 0.1 cm.sup.2 and the surface area of the clinical device
is 0.00078 cm.sup.2 (0.3 mm diameter). FIG. 9A shows normalized
elution profiles in ng per device per day over 100 days for bulk
sample of silicone with 1% Bimatoprost, assuming an exposed surface
diameter of 0.3 mm on the end of the device, according to
embodiments of the present invention. The normalized elution
profile is about 10 ng per day. The data show approximately zero
order release kinetics from about ten days to about 90 days for
each of the formulations. These data are consistent with particles
of Bimatoprost suspended in a drug core matrix and substantial
saturation of the drug core matrix with Bimatoprost dissolved
therein, as described above. Similar formulations can be used with
drug core sheaths and a shaped exposed surface of the core exposed
to the tear to increase the exposed surface area as described above
and deliver the drug in therapeutic amounts over an extended
period.
[0148] In some embodiments, the core can comprise a 0.76 mm
diameter core with an exposed surface diameter of 0.76 mm,
corresponding to an exposed surface area of 0.0045 cm.sup.2. The
core can be covered with a sheath to define the exposed surface of
the core as described above The normalized elution profile for such
a device, based on the bulk sample data above, is approximately 6
times (0.0045 cm.sup.2/0.00078 cm.sup.2) the elution profile for
the device with a 0.3 mm diameter exposed surface area. Thus, a
zero order elution profile with an elution rate of about 60 ng per
day can be obtained over a period of about 90 days. If the exposed
surface area is increased to about 0.0078 cm2, for example with
many of the exposed surface shapes as described above, the zero
order elution rat is about 100 ng per day over a period of about 90
days. The concentration can also be increased from 1%. Similar
elution profiles can be obtained with Latanoprost.
Example 4
Latanoprost Elution Data
[0149] Drug cores were manufactured as described above with
Latanoprost and silicone 4011, 6385 and/or NaCl. Four formulations
were manufactured as follows: A) silicone 4011, approximately 20%
Latanoprost, and approximately 20% NaCL; B) silicone 4011,
approximately 20% Latanoprost, and approximately 10% NaCl; C)
silicone 4011, approximately 10% Latanoprost, and approximately 10%
NaCl; and D) silicone 6385, approximately 20% Latanoprost. FIG. 10A
shows profiles of elution of Latanoprost form the cores for four
formulations of Latanoprost, according to embodiments of the
present invention. The results show initial rates of approximately
300 ng per device per day that decreases to about 100 ng per device
per day by 3 weeks (21 days). The results shown are for non-sterile
drug cores. Similar results have been obtained with sterile drug
cores of Latanoprost. These data are consistent with droplets of
Latanoprost suspended in a drug core matrix and substantial
saturation of the drug core matrix with Latanoprost dissolved
therein, as described above
[0150] While the exemplary embodiments have been described in some
detail, by way of example and for clarity of understanding, those
of skill in the art will recognize that a variety of modification,
adaptations, and changes may be employed. For example, multiple
delivery mechanisms may be employed, and each device embodiment may
be adapted to include features or materials of the other, and
further multiple features or multiple materials may be employed in
a single device. Hence, the scope of the present invention may be
limited solely by the appending claims.
* * * * *